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nological RNA phage VLP applications, such as experimental 
vaccines constructed by genetic fusion and chemical cou-
pling methodologies, nanocontainers for targeted drug de-
livery, and bioimaging tools.  © 2016 S. Karger AG, Basel 
 Family of RNA Phages 
 Taxonomy 
 Pili-specific RNA phages, currently the most promis-
ing virus-like particle (VLP) carriers, are nonenveloped, 
spherical viruses with T = 3 icosahedral symmetry and 
diameters ranging from approximately 28 to 30 nm. RNA 
phage particles are composed of 178 chemically identical 
coat protein (CP) molecules, or 89 CP dimers, and one 
copy of maturation, or A, protein, which replaces a single 
CP dimer. The phage’s monopartite, positive-sense, sin-
gle-stranded (plus-ssRNA) genome is approximately 4 kb 
in size and serves as messenger RNA for the synthesis of 
the capsid-forming CP as well as three other viral pro-
teins: the maturation, replicase, and lysis proteins ( fig. 1 ).
 The first  Escherichia coli -infecting RNA phages that 
played an important role in VLP technology were identi-
fied in the early 1960s and included the f2  [1] , MS2  [2] , 
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 Abstract 
 RNA phages are often used as prototypes for modern re-
combinant virus-like particle (VLP) technologies. Icosahedral 
RNA phage VLPs can be formed from coat proteins (CPs) and 
are efficiently produced in bacteria and yeast. Both genetic 
fusion and chemical coupling have been successfully used 
for the production of numerous chimeras based on RNA 
phage VLPs. In this review, we describe advances in RNA 
phage VLP technology along with the history of the Leviviri-
dae family, including its taxonomical organization, genomic 
structure, and important role in the development of mole-
cular biology. Comparative 3D structures of different RNA 
phage VLPs are used to explain the level of VLP tolerance to 
foreign elements displayed on VLP surfaces. We also sum-
marize data that demonstrate the ability of CPs to tolerate 
different organic (peptides, oligonucleotides, and carbohy-
drates) and inorganic (metal ions) compounds either chem-
ically coupled or noncovalently added to the outer and/or 
inner surfaces of VLPs. Finally, we present lists of nanotech-
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R17  [3] , fr  [4] , M12  [5] , and Qβ  [6] phages. The early his-
tory and basic properties of RNA phages were reported in 
detail in two books  [7, 8] and in one original review  [9] .
 Later, other RNA phages that became more common 
as VLP carriers were described, including the  E. coli phag-
es SP, FI  [10] and GA  [11] , the  Caulobacter crescentus 
phage φCB5  [12] , the  Pseudomonas aeruginosa phage 
PP7  [13] , the broad host range, P-pili-specific phage 
PRR1  [14] , and the  Acinetobacter phage AP205  [15,  16] .
 According to the most current ICTV taxonomy release 
 [17] , RNA phages are members of the family Leviviridae. 
This family has not been assigned to any higher viral or-
der and comprises two genera:  Levivirus , which  includes 
the species BZ13 (first mentioned in Inokuchi et al.  [18] ) 
and MS2, and  Allolevivirus , which includes the species FI 
and Qβ. Other common RNA phages were mentioned in 
earlier ICTV taxonomy releases until 1998.
 According to current NCBI Taxonomy browser infor-
mation  [19] , the  Levivirus genus consists of the BZ13 and 
MS2 species. The BZ13 species includes the phages GA 
and JP34, among others, as subspecies, while the MS2 
species includes the phages f2, fr, M12, and R17, among 
others. The  Levivirus genus also includes some unclassi-
fied members such as the  Acinetobacter phage AP205 and 
the  Pseudomonas phage PP7.
 Based on the NCBI Taxonomy classification of the  Al-
lolevivirus genus, the FI and Qβ species include FI group 
subspecies (including phages SP, TW19, and TW28, 
among others) and Qβ group subspecies (including phag-
es MX1 and ST, among others). Some species, including 
the  Caulobacter phage φCB5 and P-pili-specific phages, 
predominantly the  Pseudomonas phage PRR1, remain in 
the NCBI classification as unclassified Leviviridae  mem-
bers.
 Sero- and Genogroups 
 Generally, the current classification is based on sero-
logical typing  [20] and has divided RNA phages into four 
serogroups, namely, serogroups I to IV [for a detailed dis-
cussion, see  21 ]. This classification scheme has been con-
firmed by studies of the template specificity of RNA phage 
replicases  [22] , genetic analysis  [23, 24] , and physiochem-
ical data, e.g. by resistance to high hydrostatic pressure 
 [25] . The RNA phages MS2, GA, Qβ, and SP are typically 
recognized as reference strains for the sero- and geno-
groups I, II, III, and IV, respectively. Therefore, group I 
and II members belong to the  Levivirus genus, while se-
rogroup III and IV members belong to the  Allolevivirus 
genus. Ecological and wastewater studies have revealed 
that RNA phages from groups II and III are associated 
with human waste, whereas group I and IV members are 
predominantly associated with animal waste  [21] . How-
ever, this distribution is not absolute and requires further 
refinement  [26, 27] .
 The genomic structures of the  Levivirus and  Allolevi-
virus genera members demonstrate some differences 
( fig. 1 ). In addition to the standard maturation protein, 
CP, and replicase subunit, the  Allolevivirus genome en-
codes a C-terminally extended CP known as the minor 
A1 protein, which appears as a result of ribosomal read-
through of a leaky opal termination codon of the CP gene 
 [28] and is essential for the formation of viable Qβ par-
ticles in vivo  [29–31] . The A1 protein is incorporated in 
3–10 copies per virion, or in 12 copies in accordance with 
a recent study  [32] , it is required for infection, but its pre-
cise function is not known [for more references, see  8, 
29–33 ]. A recent electron microscopy visualization of for-
eign epitopes carried by A1 protein within infectious Qβ 
particles showed that the A1 protein molecules are occu-
pying corners of the Qβ icosahedron  [32] . The lysis pro-
tein forms pores in the cellular membrane, leading to ac-
tivation of autolysins and, eventually, cell lysis  [34] .
 Drawbacks of Classification 
 The current NCBI classification comprising two gen-
era as well as four serogroups are adequate in the case of 
coliphages; however, attempts to assign phages from 
other hosts to  Levivirus ,  Allolevivirus, or ‘unclassified’ 
members have been rather artificial and lack solid ratio-
nale aside from historical considerations. In our opin-
ion, a new classification system based solely on sequence 
similarities should be employed. For example,  Levivirus 
and  Allolevivirus genera could be left only for coliphag-
es, and new genera could be introduced based on se-
quence similarities among conserved replicase protein 
sequences.
 Unique Scientific Role 
 RNA phages were the first classic models used in early 
molecular biology and are considered ‘instrumental in 
the making of molecular biology’  [35] . They provided the 
scientific community with purified RNA and markedly 
contributed to the decryption of the genetic code, the un-
derstanding of RNA translation and replication mecha-
nisms, and the elucidation of virus–host interactions and 
the self-regulation of biological systems [for details and 
references, see  7–9, 35 ]. The RNA phage MS2 was the first 
organism with a fully sequenced genome  [36] . The cap-
sids of the RNA phages R17 and f2 were among the first 
observed virions with resolved icosahedral symmetry 
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 [37] , after the classical work by Caspar and Klug  [38] on 
the structural analysis of plant viruses. RNA phages have 
also presented substantial background for studies on phy-
logeny and genome evolution  [33] .
 Furthermore, RNA phages paved the way for anti-
sense-based gene therapy via the generation of the so-
called ‘mRNA-interfering complementary RNA (mi-
cRNA) immune system’ for the prevention of phage SP 
proliferation  [39, 40] .
 RNA phages, especially the phage MS2, have also 
markedly contributed to ecological and disinfection stud-
ies via their use in the development of numerous physical 
and chemical methods for genome inactivation, from ear-
ly attempts  [41] to recent systematic studies  [42] . The 
RNA phages MS2, GA, Qβ, FI, SP, and PP7 are still effi-
ciently used as surrogate models for the control of viral 
contamination in food production and storage, in indus-
trial and clinical applications, and on health care person-
nel [for two recent examples, see  43, 44 ], in addition to 
serving as viral and microbial source tracking materials 
in wastewater [for references and discussion, see  45 ]. It is 
broadly accepted that RNA phages are fully adequate sur-
rogates for human enteroviruses in studies of virus con-
tamination  [46, 47] . RNA phages are also often used as 
internal controls of extraction/amplification efficiency in 
modern RT-PCR kits for the surveillance of emerging 
pathogens, including the Ebola virus  [48] .
 CP as a Repressor 
 RNA phages were the first examples of an ‘operon’ 
mechanism of gene regulation by ‘self’ proteins  [49] . This 
mechanism can be described as a full-cycle regulated bi-
ological system, where gene regulation is performed by 
two phage proteins: CP and replicase  [50, 51] . The CPs 
of most RNA phages have been shown to repress transla-
tion of the replicase gene by binding to an RNA hairpin 
as an operator at the start site of the replicase gene  [7–9] . 
The ability of RNA phage CP to recognize the corre-
sponding operator stem-loop led to the development of 
an efficient methodology based on the tethering of CP to 
a
b
 Fig. 1. Genomic structure of RNA phages 
that have been used in viral nanotechnol-
ogy applications.  a Locations of the CP 
genes (colored in dark pink) within the ge-
nomes of RNA phages. The genomes are 
shown to scale and are in alphabetical or-
der. AP and A2 are maturation proteins. 
RP = Replicase; L = lysis protein. The Qβ 
genome does not encode L protein. The A1 
extension of the Qβ CP is indicated in light 
pink. The numbering used for CP aa resi-
dues is indicated for each species. The data 
are compiled from the NCBI taxonomy 
browser for the Leviviridae family  [19] . The 
experimentally determined lengths of 
phage CPs are always one aa residue short-
er than the actual proteins because the N-
terminal methionine is cleaved off in in-
fected  E. coli cells. This explains the dis-
crepancies in CP numbering in different 
published works.  b The phenogram of
the CP aa sequences obtained by Clustal V 
alignment in the MegAlign program from 
DNASTAR Lasergene. 
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CP-operator-tagged RNAs. Using this technique, 
mRNAs that are tagged with the operator sequence are 
highly specifically recognized by CP, which can be fused 
to fluorescent or other functional probes. This CP-oper-
ator tethering methodology enables imaging of the pro-
cessing, export, localization, translation, and degrada-
tion of operator-tagged mRNA in living cells (see the re-
view by Lampasona and Czaplinski  [52] and a recent 
protocol from Bensidoun et al.  [53] as an example). Fur-
thermore, the tethering technique allows affinity purifi-
cation of the desired RNA-protein complexes  [54] . The 
tethering methodology mostly exploits the CP-operator 
composition from phage MS2, although PP7-based 
methodology, including the use of simultaneous MS2 
and PP7 two-color labeling  [55] , has been recently de-
scribed. A phage R17-based technique was also used in 
the early development of the tethering approach  [56] . It 
is noteworthy that the tethering technique has recently 
been applied to further develop the highly productive 
CRISPR-Cas9 technology  [57] .
 Expression and Structural Investigations 
 Expression of CP Genes 
 The expression of RNA phage CP genes in  E. coli led 
to the high-level production of correctly self-assembled 
icosahedral capsids that were morphologically and im-
munologically indistinguishable from virions in the case 
of MS2  [58, 59] and fr  [60] of group I, JP34, an intermedi-
ate between groups I and II  [61] , GA of group II  [62] , Qβ 
of group III  [63] , SP of group IV  [64] , the unclassified 
 Levivirus members PP7  [65, 66] and AP205  [67, 68] , and 
the unclassified Leviviridae phages PRR1  [69] and φCB5 
 [70] . It is noteworthy that not only  E. coli cells but also the 
 E. coli -based cell-free translation system can be used for 
efficient in vitro production of MS2 VLPs  [71, 72] .
 Coinfection with two phages led to the production of 
mixed particles only in the case of the closely related 
phages MS2 and fr from the serogroup I and not in the 
case of the more distantly related phages fr and GA; how-
ever, the reassembly of recombinant fr and GA CP dimers 
in vitro allowed the generation of the mixed particles in 
both spherical and rod-like configurations  [73] .
 Highly efficient production of VLPs was also achieved 
in the yeast species  Saccharomyces cerevisiae and  Pichia 
pastoris for phages MS2  [74] , Qβ  [75] , GA  [76] , fr, AP205, 
PP7, and φCB5  [77] . Attempts to prepare RNA phage SP 
VLPs in  S. cerevisiae and  P. pastoris  were unsuccessful 
 [77] .
 3D Structures of Phage Capsids 
 As mentioned above, the RNA phages R17 and f2 
played a unique role in revealing the virion’s icosahedral 
symmetry  [37] . The place of RNA phages in the global 
history of viral architecture was presented in a recent re-
view  [78] . Early electron microscopy studies demonstrat-
ed clear paracrystalline arrays of virions in  E. coli cells 
infected with the RNA phages f2  [79] , μ2  [80] , and R17 
 [81] . Similar paracrystalline structures were later found 
in  E. coli cells expressing the CP gene and producing 
VLPs; for example, see the electron micrograph of a slice 
of a cell filled with phage Qβ VLPs in Pumpens and Grens 
 [82] .
 Fine 3D structures of the most typical RNA phage rep-
resentatives have been resolved by X-ray crystallography 
( fig.  2 ) and were found to be very similar, despite the 
marked diversity in the primary structures of their CPs 
( fig. 1 ). The first 3D structure resolved was for MS2 viri-
ons. At the time, this structure showed no similarity to 
any other known viruses or proteins of any origin. The 
MS2 virion structure was first determined at a resolution 
of 3.3 Å  [83–85] and then refined to a resolution of 2.8 Å 
 [86] . Next, the crystal structure of an MS2 capsid with 
amino acid (aa) exchanges in the FG loop was resolved 
 [87] . Historically, the first phage MS2 crystals and pre-
liminary X-ray examination data were obtained in Walter 
Fiers’ lab in 1979  [88] .
 According to the 3D structure of MS2, the 180 CP sub-
units of the virion are arranged in dimers as initial build-
ing blocks and form a lattice with a T = 3 triangulation 
number ( fig. 2 ). The CP subunit consists of a five-strand-
ed β-sheet facing the inside of the particle and a hairpin 
and two α-helices on the outside.
 The structure of a recombinant capsid of the RNA 
phage fr was determined by X-ray crystallography at a 
resolution of 3.5 Å and was shown to be identical to the 
protein shell of the native virus  [89, 90] . This was followed 
by determination of the structure of the GA phage, which 
showed some structural differences compared to MS2 
and fr phage/VLPs, especially in the N- and C-terminal 
regions  [91] . The structures of virions and recombinant 
capsids of the Qβ phage were resolved at a resolution of 
3.5 Å  [92, 93] . These structures differed from previously 
determined RNA phage structures by the presence of sta-
bilizing disulfide bonds on each side of the flexible FG 
loop, which covalently links CP dimers. A comparison 
with the structure of the related phage MS2 shows that 
although the fold of the Qβ CP is very similar, the details 
of the protein-protein interactions are completely differ-
ent  [93] .
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 Fig. 2. Crystal structures of RNA phages that have been used as 
VLP carriers. The structures are presented in alphabetical order 
with their protein data bank IDs shown in parentheses and the 
outer diameters indicated for each species. The AB loops are ex-
posed on the full-capsid surfaces. Also shown are the correspond-
ing trimeric asymmetric units with the indicated N- and C-termi-
ni. The outer surface is oriented towards the reader. The AB loops 
are indicated by arrows. The Qβ AB loops are distinguished by 
Lys14 residues, which are indicated by the shaded areas. The CP 
chains A, B and C are indicated in red, green, and blue, respec-
tively. The structural data are compiled from the VIPERdb
(http://viperdb.scripps.edu) database  [389] and were visualized 
using Chimera software  [390] . 
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 The crystal structure of the  P. aeruginosa phage PP7 
was resolved at a resolution of 3.7 Å  [94, 95] . As in the 
case of the MS2 and Qβ CPs, the RNA recognition site on 
the PP7 CP was determined  [96] . Recently, a detailed bio-
physical study of PP7 virions, including the effects of pH 
and salt concentration on the charge transition from net-
positive to net-negative, was undertaken  [97] . The crystal 
structure of another  Pseudomonas  phage, PRR1, was re-
solved at a resolution of 3.5 Å and exhibited a binding site 
for a calcium ion close to the quasi-3-fold axis  [69] .
 The crystal structure of a very distant RNA phage, the 
 Caulobacter phage φCB5, was resolved at 3.6 Å, and the 
structure of a φCB5 VLP was resolved at 2.9 Å  [70] . The 
structures appeared to be nearly identical, with some dif-
ferences in the average density of RNA. Unlike in other 
phages, φCB5 capsids are significantly stabilized by cal-
cium ions, similarly to some plant viruses  [98] . Disassem-
bly of these capsids occurs when the calcium ions are che-
lated with EDTA and/or there is a reduction in the sur-
rounding salt concentration. Another unique feature of 
φCB5 is the involvement of RNA bases in the stabilization 
of its interdimer contacts  [70] .
 Recently, the crystal structure of a phage AP205 dimer 
was solved at a resolution of 1.7 Å and then fitted into a 
6.6-Å resolution cryo-EM map  [99] . The structure of the 
AP205 CP dimer can be regarded as a circular permutant 
relative to the structures of MS2 and other family mem-
bers ( fig. 3 ). This feature is made possible by the fact that 
 Fig. 3. Differences in CP structures be-
tween the AP205 and MS2 phages. The 
overall folds of the CP dimers (top) are 
similar for both phages. The CP monomers 
are shown in rainbow coloring, from the 
blue N-terminus to the red C-terminus. 
From the more schematic picture of sec-
ondary structure elements (middle), it is 
obvious that AP205 has N- and C-termini 
that are located in roughly the same place 
as the AB loops from MS2. As a result, the 
N- and C-termini in AP205 are well ex-
posed on the capsid surface (blue and red, 
respectively), similarly to the AB loops 
(black) in MS2. 
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the N-terminus of one monomer in the dimer is in close 
proximity to the C-terminus of the other monomer. 
Compared to MS2 and other phages with known struc-
tures, the AP205 CP is missing one beta strand in its N-
terminus, but it has an extra beta strand in its C-terminus. 
However, when considered from a 3D perspective, the 
position of the beta strand is essentially the same in both 
cases. As a consequence, AP205 has N- and C-termini in 
the same locations as those occupied by surface-exposed 
AB loops in other phage capsids. It is notable that the N- 
and C-termini in other phages are not well exposed on the 
surface and are clustered around the quasi-3-fold axes. 
This explains the previous observations that, in contrast 
to other phages, the AP205 CP can tolerate long additions 
at its N- and C-termini without compromising capsid as-
sembly  [67] .
 In addition to the structures of self-assembled RNA 
phage capsids, the crystal structures of unassembled mu-
tant CP dimers of MS2  [100] and GA  [62] have also been 
resolved. These structures showed only minor differences 
in comparison to their self-assembled counterparts. Sur-
prisingly, the MS2 CP sustained a genetic fusion, result-
ing in a duplicated CP that folded normally and func-
tioned as a translational repressor due to its physical 
proximity to the N- and C-termini of the CP  [101] .
 Furthermore, the crystal structure of an icosahedral 
MS2 capsid that was assembled from covalently joined 
dimers, or so-called single-chain dimers, was resolved at 
4.7 Å  [102] . The structure resembled the wild-type (wt) 
virion except for the intersubunit linker regions, but a 
fraction of the capsids was unstable in phosphate buffer 
because of assembly defects  [102] . Moreover, the organi-
zation of MS2 single-chain dimers into crystals may have 
resulted in an arrangement of subunits that corresponds 
to T = 3 octahedral particles  [103] . In this case, the ar-
rangement of dimers is somewhat similar to that in nor-
mal T = 3 icosahedral particles, except that four FG loops 
interact near the 4-fold axis of symmetry on an octahe-
dron rather than five FG loops interacting near the 5-fold 
axis of symmetry on an icosahedron. However, when 
MS2 CP dimers are not crystallized in the F cubic crystal 
form, they are assembled into T = 3 icosahedral capsids 
that are indistinguishable from the wt particles  [103] .
 Structural Basis of RNA Recognition 
 X-ray crystallography led to a breakthrough in under-
standing the protein-RNA interactions that occur during 
translational repression and genome encapsidation. This 
breakthrough was particularly apparent after the first 
crystal structure of a complex of recombinant MS2 cap-
sids with the 19-nucleotide RNA operator was resolved at 
2.7 Å  [104–106] . The residues responsible for the protein-
RNA interactions were localized by analysis of aa ex-
changes at positions 45 and 59  [107–109] . Furthermore, 
numerous other mutations responsible for altering the 
specificity  [110] and efficiency  [111] of translational op-
erator complexes were identified. The crystal structures 
of MS2 VLPs complexed with RNA aptamers, which dif-
fer in secondary structure from wt RNA  [112–114] or in-
volve the presence of 2 ′ -deoxy-2-aminopurine at the crit-
ical –10 position  [115] , have also been resolved.
 Structures of CPs in complex with operator RNA frag-
ments have also been solved for PRR1  [116] , PP7  [117] , 
and Qβ  [118] . The CP dimers formed by the RNA phages 
studied to date all recognize a stem-loop sequence around 
the replicase start codon. This CP-RNA interaction serves 
as a mechanism for translational repression and self-ge-
nome recognition during virion assembly. Although the 
overall binding mode of the stem-loop to CP is similar in 
all the studied cases, the details are surprisingly different 
among different viruses. A number of nucleotides form 
sequence-specific and sequence-unspecific interactions 
with CPs. For CP recognition, the most important nucle-
otides are two adenosines, one located in the loop region 
and another in a stem bulge. In MS2, PP7 and Qβ, these 
adenosines form quite different interactions with the CP 
dimer ( fig. 4 ). It should be noted that we have failed to 
identify analogous CP-RNA interactions in the more dis-
tantly related phages AP205 and φCB5 [K. Tars, unpubl. 
observations], suggesting that mechanisms of genome 
recognition and translational repression may differ sig-
nificantly among distant Leviviridae  family members.
 Electron cryomicroscopy studies have shown that, in 
addition to the operator, many other RNA sequences in 
the MS2 genome are able to bind to the CP dimer  [119] . 
Such studies have allowed 3D visualization of icosahe-
drally averaged genomic MS2 RNA at a resolution of 9 Å 
 [120] . Recently, direct evidence for packaging signal-me-
diated assembly of the MS2 phage was presented based on 
cross-linking studies of peptides and oligonucleotides at 
the interfaces between the capsid proteins and the ge-
nomic RNA of this phage  [121, 122] . Remarkably, the 
same CP-RNA and maturation protein-RNA interfaces 
were identified in every viral particle.
 The A Protein 
 Particles of RNA phages contain a single copy of a mat-
uration protein, also known as the A protein, which binds 
to genomic RNA and is absolutely necessary for the infec-
tivity of phages by attachment to bacterial pili. Therefore, 
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the A protein must be exposed at both the inner and out-
er surfaces of the CP shell. Because the capsids of ssRNA 
phages contain holes at the 5-fold and 3-fold axes of sym-
metry that are large enough for the diffusion of RNA frag-
ments, it was long believed that the A protein binds in 
proximity to these axes. However, it was recently shown 
in cryo-EM studies that the A protein actually replaces a 
single CP dimer  [123, 124] ; as such, the virion actually 
contains 178 CP monomers.
 Comparative investigations of MS2 VLPs and virions 
containing a copy of the A protein by SANS (small-angle 
neutron scattering) revealed some differences, particu-
larly the presence of ‘thin’ (preinfection) and ‘thick’ 
(postinfection) capsids, which are not seen by crystallo-
graphy  [125] . The role of the A protein during virus as-
sembly may involve the accumulation of tension that is 
later used to eject the genomic RNA and the A protein 
into a host cell.
 Intrinsic Antigenicity and Immunogenicity 
 Species-specific virus-neutralizing antibody responses 
to RNA phages were studied in the late 1960s  [126–129] . 
The MS2 phage was characterized as a T cell-dependent 
antigen that may also function as a T cell-independent 
antigen when used in high doses  [130] , with high efficacy 
in inducing T cell response  [131] . However, no B cell epi-
topes have been mapped for virus-neutralizing antibodies 
on RNA phage capsids. General observations have shown 
the conformational nature of the B cell epitopes [our un-
publ. data]. It was found that only a synthetic MS2 CP 
peptide spanning from positions 89 to 108 is capable of 
inhibiting phage neutralization by specific antiserum and 
of inducing the production of virus-neutralizing antibod-
ies in rabbits  [132] and guinea pigs  [133] . Chemical con-
jugation of an N-acetylmuramyl- L -alanyl- D -isogluta-
mine (MDP) adjuvant to the 89–108 peptide also mark-
edly increased the induction of virus-neutralizing 
 Fig. 4. Different binding modes of operator stem-loop sequences to CP dimers from MS2, Qβ, and PP7. For the 
operator stem-loop sequences, adenosine, which is required for the binding of loop nucleotides, is shown in red, 
while bulged adenosine is shown in blue. The replicase gene initiation codon is boxed. 
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antibodies in rabbits  [134] . Although proper CP epitopes 
have not been mapped, the epitope-recognizing comple-
mentarity-determining region (CDR) peptides from a vi-
rus-neutralizing monoclonal antibody specific for phages 
fr, MS2, and GA were described and documented for 
their capability to neutralize the abovementioned phages 
 [135] . Recently, CDRs from thermostable single-domain 
anti-MS2 antibodies obtained by the immunization of
llamas were sequenced  [136] .
 RNA Phage Coats as a VLP Carrier 
 Genetic Fusion as a First Step in the Development of 
RNA Phage VLP Carriers 
 Recombinant capsids of fr  [137, 138] and MS2  [139] 
were the first VLP carriers proposed for the presentation 
of foreign immunological epitopes on their surfaces by 
genetic fusion. To identify appropriate CP regions, oligo-
nucleotide linkers encoding short aa sequences and con-
taining convenient restriction sites were inserted into dif-
ferent regions of the fr CP  [140] . Remarkably, this work 
was based on computer predictions of the spatial struc-
ture of the fr CP and was conducted before the first crys-
tal structure of an RNA phage, namely that of the homol-
ogous MS2 capsid, had been resolved  [83–86] . Recombi-
nant fr CPs containing 2- to 12-aa-long additions to their 
N- or C-termini or insertions at position 50 in the RNA-
binding region were capable of self-assembly, but this was 
not the case at positions 97–111 in the αA-helix  [140] . 
The majority of other fr CP mutants demonstrated re-
duced self-assembly capabilities and formed either CP di-
mers (aa exchanges at residues 2, 10, 63, or 129) or both 
dimer and capsid structures (residue 2 or 69)  [141] . The 
FG loop of the fr CP was also recognized as a potential 
target for insertions/replacements and was initially mod-
ified by a 4-aa-long deletion  [142] . The deletion variant 
retained the ability to form capsids, although they dis-
played significantly reduced thermal stability. Further-
more, the 3D structures of the mutant capsids revealed 
that the modified loops were disordered near the 5-fold 
axis of symmetry and were too short to interact with each 
other  [142] . Because of the high importance of the FG 
loop in capsid stability, further development of chimeras 
based on the implementation of FG loops was not pur-
sued.
 Vectors were constructed for the insertion of foreign 
sequences into codon position 2 of the fr CP-coding se-
quence in all possible reading frames  [137] . When the 
preS1 epitope DPAFR from hepatitis B virus (HBV) was 
inserted as a marker at positions 2, 10, and 129, it ap-
peared in all cases on the particle surface  [137] . Attempts 
to introduce the 40-aa-long V3 loop from the human 
immunodeficiency virus 1 (HIV-1) gp120 protein into 
the N-terminus, at positions 10, 12, and 15, or into the 
FG loop led to unassembled products [K. Tars, unpubl. 
data].
 Attempts to use the N-terminal β-hairpin exposed at 
the surface of the capsid, namely aa residues 15/16, al-
lowed for the production of MS2 capsids bearing a num-
ber of different peptide sequences up to 24 aa residues in 
length  [139] . Foreign epitopes exposed on these chimeras 
were found to be immunogenic in mice  [139] . Mutation-
al mapping revealed residues that are responsible for in-
ter- and intramolecular contacts and therefore for the 
thermal stability of MS2 capsids  [143] .
 The addition of the Flag octapeptide to the N-terminus 
or its insertion into the N-terminal β-hairpin of the MS2 
CP prevented self-assembly and proper folding, respec-
tively. However, genetic fusion of the Flag to a duplicated 
CP-encoding sequence resulted in the synthesis of a pro-
tein considerably more tolerant to the structural pertur-
bations and mostly corrected the defects accompanying 
Flag peptide insertion  [144] . The putative protective epi-
tope T1, spanning 24 aa in length and derived from the 
immunodominant liver stage antigen-1 of the malaria 
parasite  Plasmodium falciparum , was inserted at the tip 
of the N-terminal β-hairpin (between positions 15 and 
16) of the MS2 CP  [145] .
 fr VLPs have shown unusually high capacities as vec-
tors, particularly when the addition of long segments of 
hamster polyomavirus VP1 to the N-terminus of the fr 
CP did not prevent VLP self-assembly  [146] . When dis-
covered, these findings markedly enhanced interest in us-
ing RNA phage coats as potent vaccine candidates.
 However, the relatively low tolerance of fr- and MS2-
based VLP vectors to long foreign insertions represents a 
clear limitation of these models. For example, the fr CP 
failed to form VLPs following the insertion of long HBV 
preS1 sequences  [147] . To overcome this difficulty, Qβ 
protein A1, namely the C-terminal extension of the Qβ 
CP within the A1 protein, has been proposed as a site for 
foreign insertions  [148, 149] . Potentially, the 195-aa ex-
tension of the Qβ CP could be considered an ideal target 
for insertions. This region was found to contain elements 
that typically protrude as spike-like structures on the par-
ticle surface. Furthermore, the self-assembly capabilities 
of capsids with mutually exchanged extensions of the Qβ 
and SP CPs were confirmed experimentally  [64] . A fol-
lowing mathematical prediction showed possible colin-
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 2
/2
/2
01
7 
12
:1
9:
01
 P
M
 RNA Phage Capsids as Nanotools  Intervirology 2016;59:74–110 
DOI: 10.1159/000449503
83
earity between the Qβ CP extension and the surface-lo-
cated HBV preS sequence  [148] . It is noteworthy that the 
crystal structure of the read-through domain from the Qβ 
A1 protein was recently determined at a resolution of
1.8 Å and revealed a fold that is unique among all proteins 
found in the protein data bank  [150] .
 Qβ CP proteins with additions at their C-termini failed 
to form particles in most cases. However, such additions 
were incorporated into particles in the presence of a wt 
‘helper’ CP to form mixed, or mosaic, particles. Mosaic 
VLPs differ therefore from chimeric VLPs which are built 
from identical recombinant CP molecules, without any 
helper molecules. Such mosaic particles were constructed 
by either enhancing the level of UGA suppression in the 
presence of overexpressed suppressor tRNA  [151] or by 
exchanging the UGA stop codon to a GGA sense codon 
and expressing the extended and helper forms of the Qβ 
CP from two separate genes. These genes were located 
either on the same plasmid or on two separate plasmids 
with different antibiotic resistance genes. Potential inser-
tion sites were mapped by insertion of the 5-aa preS1 
DPAFR model epitope and the 39-aa-long HIV-1 gp120 
V3 loop  [149] . After enhancing UGA suppression, mo-
saic particles were detected, but the proportion of A1 to 
helper CP in these particles dropped from 48 to 14% as 
the length of the A1 extension increased  [152] . A model 
insertion of the preS1 epitope DPAFR located on the par-
ticle surface produced specific antigenicity and immuno-
genicity in mice  [152] . The antibody response to the preS1 
epitope was higher for self-assembled Qβ-preS1 VLPs 
than for a nonassembled Qβ-preS1 variant  [153] . When 
the Qβ CP was modified to carry long HBV preS inser-
tions (full-length preS, preS1, or preS2 alone) instead of 
the A1 extension, mosaic particles formed that had sur-
face-exposed preS, but regular VLPs did not form without 
the presence of the Qβ CP as a helper [I. Cielens and R. 
Renhofa, unpubl. data].
 On Qβ CP itself, the residues responsible for RNA rec-
ognition have been mapped  [154, 155] . This was helpful 
for the development of packaging and gene transfer tech-
nologies based on the Qβ phage model. The ability of the 
RNA phage CP to package RNA in vivo  [156] demon-
strated the potential of RNA phages as gene delivery vec-
tors (see Nonvaccine Applications).
 Surprisingly, icosahedral Qβ VLPs have been convert-
ed into rods after modification of the FG loop structure 
 [157] . As mentioned above, the appearance of alternate 
VLP forms of RNA phages was further confirmed by the 
presence of rod-like structures in the case of the coassem-
bly of phage fr and GA CPs  [73] .
 The MS2 phage was found to be capable of accommo-
dating short (pentapeptide) sequences added to the N-
terminus of its CP within viable virions, although not all 
insertions were genetically stable  [158] . Following well-
known peptide display systems based on filamentous 
phages, a novel peptide display platform on MS2 VLPs 
was developed and successfully tested, including the 
identification of conformational epitopes  [159, 160] .
 As an experimental example of fusion technology,  fig-
ure 5 compares RNA phage virions, recombinant VLPs, 
and chimeric VLPs carrying long foreign insertions by 
electron microscopy. It is remarkable that the surfaces of 
some insertion-containing VLPs differ considerably from 
the surfaces of unmodified VLPs by the appearance of 
distinct knobs that are presumably formed by the inserted 
sequences. Besides VLP applications, the phage fr CP was 
successfully used in its nonassembled variant for the fine 
mapping of epitopes, primarily of HBV-derived proteins 
 [161–166] .
 Chemical Coupling to Further Develop VLP 
Technology 
 Chemical coupling of foreign oligopeptides to the sur-
face of VLPs was developed as an alternative method to 
the genetic fusion of epitope-encoding sequences. Chem-
ical coupling was initially applied to RNA phage Qβ VLPs 
in 2002  [167] by using an approach initially developed for 
another broadly used recombinant VLP, HBc (HBV core 
antigen)  [167, 168] . Model oligopeptides containing a 
free cysteine residue at the N-terminus were coupled to 
an exposed lysine residue on the Qβ VLP surface using 
the hetero-bifunctional cross-linker maleimidobenzoic 
acid sulfosuccinimidyl ester. The modified VLPs showed 
efficient induction of oligopeptide-specific antibodies in 
mice  [167] . This chemical coupling approach initiated 
the development of a panel of experimental therapeutic 
vaccines (see early reviews by Bachmann and Dyer  [169] 
and Dyer et al.  [170] , and a recent review by Bachmann 
and Jennings  [171] ). By following the lysine-cysteine oli-
gopeptide coupling methodology, an experimental West 
Nile virus vaccine was constructed on an AP205 VLP 
platform  [68] .
 Another chemical coupling approach was developed 
based on the rational design of modified MS2 VLPs that 
displayed a reactive thiol on the VLP surface as a result of 
a T15C substitution in the MS2 CP  [172, 173] . Cysteines 
are among the most useful functional groups found in 
proteins as they can bind a variety of metals and react with 
a large collection of organic reagents, and are therefore 
obvious targets for protein modification  [172] . Two cys-
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teine residues that are present in the wt MS2 CP are in-
ternally located and therefore relatively unreactive. Thio-
lated MS2 VLPs were chemically modified with 
fluorescein-5 ′ -maleimide to create the first fluorescent 
nanoparticles  [173] .
 Additional functionalization was achieved in a cell-
free protein synthesis platform by the production of MS2 
and Qβ VLPs with surface-exposed methionine ana-
logues (azidohomoalanine and homopropargylglycine) 
containing azide and alkyne side chains  [174] . Such VLPs 
can be used for one-step, direct conjugation schemes to 
display multiple ligands of interest. Using such technol-
ogy, proteins including an antibody fragment and granu-
locyte-macrophage colony-stimulating factor, as well as 
nucleic acids and poly(ethylene glycol) chains, were dis-
played on the VLP surface using Cu(I) catalyzed click 
chemistry  [174] . Surface functionalization methodology 
has not only been applied to the VLP surface but also to 
the interiors of MS2 VLPs by modification of tyrosine 
residues via a recently developed hetero-Diels-Alder bio-
conjugation reaction  [175] .
 The preparation of histidine-tagged MS2 VLPs by the 
introduction of a His 6 linker between CP codons 15 and 
16 to simplify the purification of VLP-covered RNAs is 
another example of VLP surface functionalization  [176] . 
Moreover, a set of advanced His 6 -tagged Qβ VLPs was 
generated, and their ability to complex metal-derivatized 
compounds was confirmed  [177, 178] . In parallel, VLP 
vector capacity for chemical coupling was broadened by 
the introduction of azide- or alkyne-containing unnatu-
ral amino acids, which was achieved by expression of the 
Qβ CP gene in a methionine auxotrophic strain of  E. coli 
 [179] .
 A highly specific approach for the further develop-
ment of VLP vectors was achieved by the asymmetriza-
tion of Qβ VLPs after the introduction of a single copy of 
the maturation protein A2, which allowed the production 
of VLPs with a single unique modification  [180] .
a b c
d e f
 Fig. 5. Electron micrographs of negatively stained AP205 virions 
( a ), recombinant AP205 VLPs ( b ), chimeric AP205 VLPs carrying 
151 aa residues of human interleukin-1β at the C-terminus ( c ), GA 
virions ( d ), recombinant GA VLPs ( e ), and chimeric GA VLPs car-
rying a 61-aa-long Z HER2:  342 affibody at the C-terminus ( f ). VLPs 
are purified from the appropriate gene-expressing  E. coli cells. For 
electron microscopy, the grids with the adsorbed particles were 
stained with aqueous solutions of 1% uranyl acetate (pH 4.5) or 2% 
phosphotungstic acid (pH 7.0) and examined with JEM-100C or 
JEM-1230 electron microscopes (Jeol Ltd., Tokyo, Japan) at 100 
kV. Well-ordered knobs are clearly visible on the surfaces of the 
chimeric VLPs. 
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 Recently, a novel plug-and-display system was estab-
lished for modular RNA phage VLP functionalization via 
further decoration of VLPs with peptides of interest  [181, 
182] . The decoration of VLPs is based on the so-called 
bacterial superglue approach, namely on the ability of a 
peptide (SpyTag) and a protein (SpyCatcher) to form 
spontaneous covalent isopeptide bonds between lysine 
and aspartic acid residues under physiological conditions 
 [183] . The SpyTag and SpyCatcher are split units of the 
 Streptococcus pyogenes fibronectin-binding protein FbaB 
and can form a highly stable amide bond by an irrevers-
ible reaction that occurs within minutes  [184] . The Spy-
Tag or SpyCatcher sequences were genetically fused to 
the N- and/or C-terminus of the AP205 CP. After mixing 
modified AP205 VLPs with the correspondingly linked 
peptides, the quantitative covalent coupling of the pep-
tides to the VLPs was observed  [181, 182] .
 Stability of VLPs 
 Efforts to improve the stability of natural RNA phage 
VLPs started with the development of a methodology that 
allowed the screening of bacteria for the synthesis of mu-
tant MS2 CPs with altered assembly properties  [185] and 
the selection of D11N variant CPs that formed virions 
more stable than the wt CP  [186] . The introduction of in-
terdisulfide bonds into the 5-fold axis of symmetry to 
cross-link MS2 VLPs improved their thermal stability to 
the level of that seen in Qβ VLPs, which possess natural 
intersubunit disulfide bonds  [187] . In contrast, cross-link-
ing at the 3-fold axis of symmetry resulted in variant CPs 
that were unable to self-assemble  [187] . The development 
of an  E. coli -based cell-free protein synthesis system opened 
a direct avenue for studying the role of disulfide bond for-
mation in the stability of mutant MS2 VLPs in comparison 
to Qβ and HBc VLPs  [188] . Through the construction of a 
set of Qβ CP mutants, it was found that disulfide linkages 
are the most important stabilizing elements in VLPs and 
that interdimer interactions are less important than intrad-
imer interactions for Qβ VLP assembly  [189] .
 Elucidation of the thermal stability of foreign epitope-
carrying VLPs, such as the chimeric MS2 VLPs formed by 
single-chain dimers, in comparison to natural disulfide 
cross-linked PP7 VLPs  [190] is of great importance for 
the further development of RNA phage-based nanotech-
nology. The genetic fusions of two copies of the MS2 
 [159] , PP7  [191] , and GA or Qβ [I. Cielens and A. Strods, 
unpubl. data] CPs resulted in a self-assembly-competent 
single-chain dimer that not only increased thermody-
namic stability but also considerably improved tolerance 
to foreign insertions in the AB-loop. The resultant cor-
rectly assembled VLPs encapsidated mostly their ‘own’ 
CP-encoding mRNAs.
 Vaccines and Vaccine Candidates 
 Vaccines represent the most advanced field of the 
RNA phage VLP applications due to the excellent and 
well-established scaffold properties and structural toler-
ance to the decoration by foreign immunogenic sequenc-
es. Such decoration can be performed both genetically 
and chemically, and the VLP scaffold may provide for-
eign epitopes with a strong T cell response. Moreover, 
RNA phage VLPs can serve as nanocontainers that can 
encapsulate specific adjuvants, such as immunostimula-
tory oligodeoxynucleotides or CpGs, as TLR9 ligands 
 [192] . RNA phage VLPs can also be packaged with single-
stranded or double-stranded RNA fragments as TLR7 
and TLR3 ligands, respectively  [193] . Moreover, recom-
binant RNA phage VLPs contain encapsulated bacterial 
RNA, which may act as an adjuvant. Reviews on vaccine 
applications include articles discussing RNA phage VLPs 
among other VLP candidates  [82, 169–171, 194–202] and 
articles focused either on RNA phage VLPs in general 
 [203] or on the use of specific RNA phage species, such as 
MS2 VLPs, as vaccines  [204] .
 Genetic Fusions 
 Table 1 contains a detailed list of the vaccine candi-
dates that have been constructed from RNA phage VLPs 
using genetic fusion methodology. First, the success of an 
experimental human papilloma virus (HPV) vaccine 
based on PP7 single-chain-dimer VLPs  [191, 205–209] 
developed in preclinical studies  [210] must be mentioned. 
A similar HPV vaccine candidate was constructed on 
MS2 single-chain-dimer VLPs and tested in preclinical 
studies  [210, 211] . Both PP7 and MS2 VLP-based vac-
cines were immunogenic, but the MS2-L2 VLPs induced 
a broader HPV-neutralizing antibody response. This is 
likely because of the structural context of L2 display on 
the VLPs, since L2 was displayed on the AB-loop of the 
PP7 CP, but at the N-terminus of the MS2 CP  [191] . A 
review on HPV vaccine candidates, including RNA phage 
VLP-based vaccines, was recently published  [212] . A ma-
laria vaccine based on MS2 VLPs has also been reported 
as very promising  [213, 214] . As to the selection of opti-
mal VLP carriers for such purposes, AP205 VLPs have 
demonstrated a high capacity and tolerance to foreign in-
sertions  [67] . Moreover, the AP205 VLPs represent good 
candidates for the construction of mosaic VLPs  [215] .
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Vaccine target Source of epitope Epitope 
length, 
aa1
Position of
insertion or
addition
Comments References
AP205
Acquired 
immunodeficiency: 
human 
immunodeficiency 
virus (HIV)
Coreceptor CCR5, ECL2 loops: 
mini-loop
CRSQKEGLHYTC and full-length 
loop
CRSQK…QTLKC 
12, 33 C-terminus VLPs carrying mini-loops are formed with GTAGGGSG, 
but not with GSG linker. VLPs carrying full-length loops 
are formed with both linkers
Cielens and 
Renhofa, unpubl. 
data
Coreceptor CXCR4, mini-loop:
CNVSEADDRYIC 
12 VLPs carrying mini-loops are formed with GTAGGGSG, 
but not with GSG linker
Coreceptor CXCR4, aa 1-39 39 N-terminus The epitope is definitely displayed on the VLP surface 67
Nef protein, aa 66 – 100 and
132 – 151
55 C-terminus The Nef T cell epitopes are displayed on the VLP surface
Autoimmune 
arthritis
Interleukin-1β, human 17 kDa C-terminus Chimeric VLPs display knobs on the surface (fig. 5) Jansons et al., 
unpubl. data
Interleukin-1α, murine
Interleukin-1β, murine and human
157, 152
154
Mosaic particles are formed by: (i) suppression of 
C-terminal amber or opal codons or (ii) coexpression of 
the chimeric gene with the helper CP gene. The GSG or 
GSGG linkers were used
Cielens and 
Renhofa, unpubl. 
data
Cancer, prostate Gonadotropin releasing hormone 
(GnRH), aa 1-10
10 N-terminus,
C-terminus
The VLPs carrying C-terminal fusion induce a strong 
antibody response that inhibits GnRH function in vivo
67
Chikungunya virus Glycoprotein E1, the virus-
neutralizing domain III (DIII); 
glycoprotein E2, full-length, 
domain A, domain B, domains 
A+B
84, 361, 
131, 60, 
298
C-terminus Mosaic particles formed by suppression of the C-terminal 
amber codon. The GSG linker was used in all cases
Cielens and 
Renhofa, unpubl. 
data 
HBV preS1, aa 21 – 47 27 N-terminus The SGTAGGGSGS linker was more preferable for the 
outcome than the SGG linker
preS1, aa 21 – 47, 20 – 58, 20 – 119 27, 39, 
100
C-terminus The GTAGGGSG linker was used
Hepatitis C virus E2 protein, genotype 1α, HVR 
sequence, aa 384 – 411; a 
‘consensus’ HVR sequence
28, 31 N-terminus The SGTAGGGSGS linker was used in both cases
Hypertension Angiotensin II, aa 1 – 8 8 N-terminus,
C-terminus 
Both variants display angiotensin II epitope on the VLP 
surface 
67
Influenza virus M2e protein, N-terminal 
ectodomain, consensus sequence, 
aa 2 – 24
23 N-terminus Strong M2-specific antibody response was achieved upon 
immunization in mice: protection of 100% of mice from a 
lethal influenza infection 
67, 295 
Lymphocytic 
choriomeningitis 
virus
Glycoprotein,
peptide p33:
KAVYNFATM
9 C-terminus Chimeric VLPs were formed also when different linkers 
and another epitope variant KAVYNFATMA have been 
used 
Cielens and 
Renhofa, unpubl. 
data
Obesity Ghrelin, aa 24 – 31: GSSFLSPE 8 The SGTAGGGSGS linker was more preferable for the 
outcome than the SGG linker
Gastric inhibitory peptide (GIP), 
aa 1 – 15 of mature GIP (42 aa):
YAEGTFISDYSIAMD
15
Salmonella typhi Outer membrane protein, D2 
peptide, aa 266-280
15 N-terminus,
C-terminus 
The epitope is displayed on the VLP surface 67
West Nile virus Glycoprotein E, the virus-
neutralizing domain III (DIII), aa 
296 – 406
111 C-terminus Mosaic particles. Immunization of mice resulted in the 
induction of IgG2 isotype anti-DIII antibodies 
215
fr
Hamster 
polyomavirus
VP1, aa 364 – 384, 351 – 374, 
351 – 384, 333 – 384
21, 24, 34, 
52
N-terminus Induction of anti-VP1 antibodies in rabbits and mice 146
 Table 1.  Vaccines and vaccine candidates constructed on RNA phage VLPs and viable virions by genetic fusion methodology
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Table 1 (continued)
Vaccine target Source of epitope Epitope 
length, 
aa1
Position of
insertion or
addition
Comments References
GA
HIV Coreceptor CCR5, ECL1 loop 
YAAAQWDFGNTMCQ
14 FG loop A shorter insertion without Cys residue 
GYAAAQWDFGNTG did not result in the self-assembled 
VLPs
Strods and Renhofa, 
unpubl. data
Coreceptor CCR5, ECL2a loop 
QKEGLHYTG
9 AB loop, aa 14/15 Cielens and 
Renhofa, unpubl. 
dataCoreceptor CCR5,
N-terminus,
aa 1 – 27
aa 1 – 31
27, 31 N-terminus of the 
second CP copy
Mosaic particles with the GA CP as a helper were formed 
in both cases
Coreceptor CXCR4, aa 1 – 40 40 N-terminus Four variants with different linkers and surrounding 
sequences formed VLPs 
Influenza virus M2e protein, N-terminal 
ectodomain
consensus sequence, aa 2 – 24 with 
C–terminally added G residue
24 N-terminus,
C-terminus 
The GSGS (GSRS) and GSG linkers were used for 
N-terminal and C-terminal insertions, respectively
M2e protein, N-terminal 
ectodomain
consensus sequence, aa 2 – 24 with 
C-terminally added G residue
24 N-terminus of the 
first CP copy of the 
CP single-chain 
dimer
The GSG linker was used
S. typhi Outer membrane protein, D2 
peptide, aa 266 – 280
15 N-terminus 
MS2
Cancer, ovarian A peptide mimicking the cancer-
associated antigen 125 (CA125/
MUC16)
10 AB loop of the CP 
single-chain dimer, 
aa ‘15/14’
The MS2-DISGTNTSRA VLPs induced murine antibodies 
that cross-reacted with CA125 from ovarian cancer cells 
Preoperative ovarian cancer patient plasma was assessed 
for anti-DISGTNTSRA
282 
Cholesterol lowering Proprotein convertase subtilisin/
kexin type 9 (PCSK9), aa 153 – 163, 
188 – 200, 208 – 222, 368 – 381
11, 13, 17, 
14
N-terminus of the 
CP single-chain 
dimer 
There were not as dramatic reductions in total cholesterol 
in mice immunized with recombinant MS2-PCSK9 VLPs, 
in comparison to chimeric Qβ VLPs (table 2)
296
Foot and mouth 
disease virus 
(FMDV)
VP1, FMDV O/
OZK, aa 141 – 160
20 AB loop The effective immune response in mice and protection of 
guinea pigs and swine against FMDV were achieved
297
HIV gp120 protein, V3 loop 10 AB loop of the CP 
single-chain dimer, 
aa ‘15/14’
The V3 insertion disrupted self-assembly, but was tolerated 
by the CP fusion into the single-chain dimer. High 
immunogenicity in mice. The ability to pack their own 
mRNA was demonstrated
139, 159, 298
Coreceptor CCR5, ECL2 loop 10 The ECL2 insertion disrupted self-assembly, but was 
tolerated by the CP fusion into the single-chain dimer. 
High immunogenicity in mice. Ability to pack their own 
mRNA
HPV L1 protein
L2 protein 
20
20
AB loop, 
aa ‘15/14’
139, 298
L2 protein of HPV16,
HPV18, HPV31,
aa 17 – 31
15 N-terminus and AB 
loop of the CP 
single-chain dimer
Two different epitopes were displayed on the same particle 
The strong protection of mice from genital infection with 
HPV pseudoviruses representing 11 diverse HPV types was 
demonstrated. Preclinical studies are ongoing
209 – 211 
Influenza virus Hemagglutinin, epitope 
YPYDVPDYA
9 AB loop, 
aa ‘15/14’
139, 298
M2e protein, conserved epitope 
EVETPIRNE
9 AB loop of the CP 
single-chain dimer, 
aa ‘15/14’
The scalable purification protocol for the potential 
veterinary vaccine application was elaborated
299
Malaria Plasmodium falciparum, liver stage 
antigen-1 (LSA-1), T1 epitope
24 AB loop, 
aa ‘15/14’ 
The LSA-1-carrying VLPs stimulated a type 1-polarized 
response, with significant upregulation of interferon-γ, a 
finding which corroborates naturally acquired resistance to 
liver stage malaria
139, 145, 298
P. falciparum, RH5 protein, a 
peptide SAIKKPVT
mimicking a linear epitope 
8 AB loop of the CP 
single-chain dimer, 
aa ‘15/14’
The chimeric VLPs elicited antibodies that inhibit parasite 
invasion and could form the basis of an effective vaccine 
against malaria
213 
P. falciparum, blood stage antigen 
AMA1 (apical membrane 
antigen-1)
10 The mimotope identified by VLP-peptide display induced 
murine antibodies that cross-reacted with AMA1
214
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Table 1 (continued)
Vaccine target Source of epitope Epitope 
length, 
aa1
Position of
insertion or
addition
Comments References
PP7
Flag peptide DYKDDDDK 8 AB loop of the CP 
and of the CP 
single-chain dimer, 
aa 11/12
The VLPs were highly immunogenic in mice and packaged 
their own mRNA 
191
HIV gp120 protein, V3 loop, a peptide 
IQRGPGRAPV
10 The VLPs were highly immunogenic in mice and packaged 
their own mRNA
191
HPV L2 protein of HPV16, aa 17 – 31: 
QLYKTCKQAGTCPPD
15 The VLPs were highly immunogenic in mice and packaged 
their own mRNA. The intravaginal immunization 
protected mice from genital infection with HPV16 
pseudovirions
191, 206
L2 protein of HPV1, 5, 6, 11, 16, 
18, 45, 58, aa 17 – 31
15 AB loop of the CP 
single-chain dimer, 
aa 11/12
Mice immunized with the mixture of eight L2 VLPs were 
strongly protected from genital challenge with 
pseudovirions representing 8 diverse HPV types. The 
anti-L2 antibodies persisted over 18 months and vaccinated 
mice retained protection over a year after immunization. 
For the first time in the generation of chimeric VLPs, RNA 
was removed from the VLP inside by alkaline treatment, as 
it has been performed before on nonchimeric MS2 VLPs 
[175]
205, 207
L2 protein of HPV16, aa 17 – 31, 
35 – 50, 51 – 65, 65 – 79, 65 – 85,
Consensus 65 – 85
21 (for 65 
– 85 
variant)
Insertion of HPV16 L2 aa 35 – 50 and aa 51 – 65 was 
compatible with VLP assembly, but insertion of aa 65 – 79 
was not. The VLPs displaying the 65 – 85 consensus peptide 
of high-risk HPV types induced murine sera that 
neutralized heterologous high-risk HPV pseudovirions 
208
L2 protein of HPV1, HPV16, 
HPV18, aa 17 – 31 
15 N-terminus and AB 
loop of the CP 
single-chain dimer
Two different epitopes were displayed on the same particle. 
The strong protection of mice from genital infection with 
HPV pseudoviruses representing 11 diverse HPV types was 
detected
209 
Pregnancy Human chorionic gonadotropin 
(hCG), aa 39 – 56, 45 – 55. 66 – 81, 
69 – 80, 111 – 120, 116 – 125, 
121 – 130, 131 – 140, 136 – 145
8 – 16 AB loop of the CP 
single-chain dimer, 
aa 11/12
Preincubating the hormone with antiserum elicited by 
VLPs displaying peptides 121 – 130 and 136 – 145 failed to 
inhibit hCG activity, while sera generated by immunization 
with VLPs displaying peptides 116 – 125, 126 – 135, and
131 – 140 dramatically inhibited uterine weight gain
300
Qβ
FMDV VP1 protein,
G-H loop peptide
14 C-terminally added 
to the shortened A1 
protein gene within 
the viable Qβ 
genome 
A replication-competent hybrid phage that efficiently 
displayed the FMDV peptide was achieved. The surface-
localized FMDV VP1 G-H loop cross-reacted with the anti-
FMDV monoclonal antibody SD6 and was found by 
electron microscopy to decorate the corners of the Qβ 
icosahedral shell. The hybrid phages induced polyclonal 
antibodies in guinea pigs with good affinity to both FMDV 
and hybrid Qβ-G-H loop 
32
HBV preS1 epitope:
31-DPAFR-35
31-DPAFRA-36
5, 6 A1 protein, 
C-terminal 
extension, aa 72/73, 
after aa 3, 6, 13, 19; 
as well as instead of 
the C-terminal 
extension
Mosaic particles were formed by A1-derived chimeras and 
Qβ CP helper via: (i) suppression of leaky UGA stop codon 
of the CP gene and (ii) simultaneous expression of CP 
helper and A1-derived genes obtained after the changing of 
CP-terminating UGA to strong UAA stop codon or sense 
GGA codon, respectively. The proportion of A1-extended 
to short CP in mosaic particles varied from 48 to 14% after 
increase of the length of A1 extension. The preS1 epitope 
ensured specific immunogenicity in mice
148, 149, 152
Full-length preS1 and preS2; 
preS1, aa 20 – 47, 20 – 58, or 31 – 58 
28 – 163 A1 protein, 
C-terminal 
extension, aa 18 or 
after leaky 
termination codon 
instead of the 
C-terminal 
extension 
Mosaic particles were formed by: (i) suppression of 
terminal amber or opal codons or (ii) coexpression of the 
chimeric gene with the CP helper gene. In the second case, 
it was necessary to place the chimeric gene first within the 
plasmid
Cielens and 
Renhofa, unpubl. 
data
HIV gp120 protein, V3 loop, aa
299 – 337
39 A1 protein, 
C-terminal 
extension, aa 72/73; 
after aa 19; instead 
of the C-terminal 
extension
Mosaic particles were formed 148, 149 
 The data are given in alphabetical order of the (i) phage model and (ii) vaccine target for the same phage model. 
1 When a precise number of aa residues is difficult to assess, the size of the epitopes is expressed in kDa.
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 2
/2
/2
01
7 
12
:1
9:
01
 P
M
 RNA Phage Capsids as Nanotools  Intervirology 2016;59:74–110 
DOI: 10.1159/000449503
89
Vaccine target Source of epitope Epitope 
length, 
aa1 
Coupling site Comments References
AP205
Asthma/allergy IL-5, murine 33 kDa SpyTag or SpyCatcher: 
genetically fused to the 
N-terminus and/or 
C-terminus
The VLP display led to the efficient breaking of self-
tolerance
182
Cancer Human telomerase reverse transcriptase, the 
mutant Telo epitope biotin-GAHIVMV-
DAYKPTREARPALLTSRLRFIPK
30 SpyCatcher genetically 
fused to the 
N-terminus
SpyCatcher is a genetically encoded protein designed 
to spontaneously form a covalent bond to its peptide-
partner SpyTag carrying desired epitope
181
Human epidermal growth factor receptor 
(EGFR) from glioblastoma, fusion junction 
epitope LEEKKGNYVVTDHGAHIVMV-
DAYKPTK-biotin
27
Murine proteins involved in cancer (CTLA-
4, PD-L1, Survivin and HER2)
kDa: 15 
27 30 83
SpyTag or SpyCatcher: 
genetically fused to the 
N-terminus and/or 
C-terminus
The VLP display led to the efficient breaking of self-
tolerance
182
Cardiovascular 
disease 
PCSK9, murine 84 kDa
Human 
immunodeficiency 
virus (HIV)
Six peptides covering the α-helical regions of 
gp41: 3 – 13, 3 – 17, 3 – 20, 3 – 24, P1, P8, 
provided with a C-terminal Cys residue
12, 16, 19, 
23, 40, 66
Lysine residues The gp41 peptides were coupled to AP205 VLPs 
through a bifunctional cross-linker SMPH. The 
chimeric VLPs elicited high titers of gp41-specific 
antibodies. 1, 2, or 3 peptide copies were coupled to 
each AP205 subunit 
301 
Lymphocytic 
choriomeningitis 
virus (LCMV)
Glycoprotein, the p33 peptide 
KAVYNFATM
9 Chimeric VLPs were packaged by CpG and induced 
effective CTL response in mice 
224
Malaria P. falciparum, membrane protein 1 
(PfEMP1) containing the Complex lysine 
and cysteine-rich inter-domain region 
(CIDR)
27 kDa SpyCatcher genetically 
fused to the 
N-terminus
A pair of SpyTag and SpyCatcher as a functional unit 
were used (see above). Injecting SpyCatcher-VLPs 
decorated with a malarial antigen efficiently induced 
antibody responses after only a single immunization
181
P. falciparum, Pfs25 protein
P. falciparum, circumsporozoite protein 
(CSP), CIDR, VAR2CSA, and Pfs25 proteins
kDa: 53, 
32, 118, 
40
SpyTag or SpyCatcher: 
to the N-terminus 
and/or C-terminus
The Pfs25 and VAR2CSA vaccines showed efficacy 
that is comparable with the efficacy of the best existing 
analogues
182
Salmonella typhi Outer membrane protein, D2 peptide, 
aa 266 – 280: TSNGSNPSTSYGFAN with 
N-terminal CGG linker
15 Lysine residues The vaccine preparations of 13, 56, 94, 142, and 293 
peptides per VLP were used. A phenomenon of carrier 
induced epitopic suppression could be overcome by 
high coupling densities, repeated injections and/or 
higher doses of conjugate vaccine
230
Tuberculosis Mycobacterium tuberculosis, Ag85A protein 48 kDa SpyTag or SpyCatcher: 
genetically fused to the 
N-terminus and/or 
C-terminus
182
West Nile virus 
(WNV)
Glycoprotein E, the virus-neutralizing 
domain III (DIII), aa 582 – 696 of the WNV 
polyprotein precursor
115 Lysine residues Domain III was engineered to comprise a His6 tag and 
a Cys-containing linker at its C-terminus. The 
antibodies induced in mice were able to neutralize 
virus in vitro and provided partial protection from a 
challenge with a lethal dose of WNV 
68
Qβ
Acquired 
immunodeficiency: 
feline 
immunodeficiency 
virus (FIV)
Transmembrane (TM) glycoprotein, a 
peptide containing tryptophan-rich motif, aa 
767 – 786: LQKWEDWVGWIGNIPQYLKG
20 Lysine residues Immunized cats developed antibodies that reacted 
with the epitope, but failed to recognize whole FIV. 
The coupling efficiency was never higher than 20%
302
Acquired 
immunodeficiency: 
HIV
Coreceptor CCR5, N-terminal ECL domain, 
circularized 
20 Immunized mice and rabbits generated antibodies that 
recognized native CCR5 and inhibited entry of 
pseudotype viruses bearing envelope glycoproteins 
from diverse primary strains in vitro
303, 304
 Table 2.  Vaccines and vaccine candidates constructed on RNA phage VLPs by chemical coupling methodology
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Vaccine target Source of epitope Epitope 
length, 
aa1 
Coupling site Comments References
Acquired 
immunodeficiency: 
HIV/simian 
immunodeficiency 
virus (SIV)
Coreceptor CCR5, macaque, ECL1, 
N-terminal aa 
MDYQVSSPTYDIDYYTSEPC; ECL2, a 
cyclic peptide, aa 168 – 177
DRSQREGLHYTG linked through an DG 
dipeptide spacer
20, 10 Lysine residues Immunization of mice and rats induced anti-CCR5 
antibodies that recognized native CCR5 and inhibited 
SIV infection in vitro. Equal amounts of both 
constructs were mixed to formulate the vaccine that 
was protective in macaques. The coupling efficiency 
reached 90 EC1 or 270 ECL2 peptides per particle 
305, 306
Allergy Cysteine protease, the major fecal allergen of 
the house dust mite D. pteronyssinus, Der p 1 
peptide, aa 117 – 133: 
CGIYPPNANKIREALAQTHSA
21 The vaccine was administered without adjuvants and 
found safe and immunogenic in humans after 
evaluation of different doses and routes of 
immunization 
307
Allergy, cat Fel d 1 protein, major cat allergen, a covalent 
dimer of chain 2 and chain 1 of Fel d 1 
spaced by a 15 aa-linker (GGGGS)×3 and 
added to the coding sequence for 
LEHHHHHHGGC at the C- terminus
23 kDa A single vaccination by Qβ-Fel d 1 was sufficient to 
induce protection against type I allergic reactions in 
mice. Moreover, Qβ-Fel d 1 did not induce 
degranulation of basophils derived from human 
volunteers with cat allergies. The coupling density was 
40 %, or 70 covalent Fel d 1 dimers per VLP
308
Allergy, 
rhinoconjunctivitis, 
rhinitis
A-type CpG (QbG10) was encapsulated as a 
TLR9 ligand. Mixed with house dust mite 
(HDM) extract 
– No coupling A phase I study. All patients achieved practically 
complete alleviation of allergy symptoms after 10 
weeks of immunotherapy
217
CYT003-QbG10: CpG QbG10 was 
encapsulated 
– A phase IIb study. Treatment with high-dose CYT003-
QbG10 improved disease symptoms. The QbG10 
content was approximately 20% of the total mass, 
corresponding to ~60 molecules per VLP
218, 219
Allergy, asthma CYT003-QbG10 – A successful phase IIb study 220, 221
Allergy, asthma and 
rhinitis
Two IgE peptides, different loops of the C3 
domain: ADSNPRGVSAYLSRPSPGGC and 
YQCRVTHPHLPRALMRS
20, 16 Lysine residues The vaccine induced high titers of anti-human IgE 
antibodies by preclinical studies in mice 
309
Allergy to red meat α-1, 3-galactosyl transferase, Galα3LN 
epitope. For conjugation, α-Gal trisaccharide 
and glucose were converted to their 
respective alkyne derivatives. Each alkyne 
was attached by a two-step procedure in 
which the protein nanoparticle was first 
acylated with an azide-terminated 
N-hydroxysuccinimide ester and then 
addressed by copper-catalyzed azide-alkyne 
cycloaddition
Carbohy-
drates are 
conjugat-
ed
Search for the presence of α-Gal-containing epitopes 
in the saliva of Amblyomma sculptum. Bites from the 
A. sculptum tick may be associated with the allergic 
reactions to red meat in Brazil
310 
Alzheimer disease Aβ peptide (1 – 9)-GGC: DAEFRHDSGGGC 12 Qβ-Aβ VLPs elicited anti-Aβ antibody responses at 
low doses and without the use of adjuvants
311
Aβ peptide: N-terminal Aβ(1 – 9) or 
C-terminal Aβ (28 – 40) 
12, 16 Both of these immunogens produced significant 
antibody titers without use of additional adjuvants and 
reduced Aβ levels when tissues were examined 8 
months after the first inoculation
312
CAD106 vaccine: Aβ peptide 1 – 6 DAEFRH 
plus a GGC spacer
9 CAD106 avoided activation of Aβ-specific T cells and 
was efficacious in reducing the amyloid accumulation 
in transgenic mice without evidence of unwanted side 
effects and is currently being tested in patients in a 
phase II study. Each VLP contained ~350 – 550 Aβ 
peptides
313
Atherosclerosis IL-1α, full length, containing aa linker at 
C-terminus 
17 kDa Immunization of mice reduced both the inflammatory 
reaction in the plaque as well as plaque progression
314
Autoimmune 
arthritis
IL-1α, murine, aa 117 – 270 of IL-1α 
precursor
IL-1β, murine, aa 119 – 269 of IL-1β 
precursor, both provided with aa linkers at 
C-termini
17 kDa Immunization of mice elicited a rapid and long-lasting 
autoantibody response. In the collagen-induced 
arthritis model, both vaccines strongly protected mice 
from inflammation and degradation of bone and 
cartilage. In the T and B cell-independent collagen Ab 
transfer model, immunization with the IL-1β vaccine 
strongly protected from arthritis, whereas 
immunization with the IL-1α vaccine had no effect. 
The coupling efficiency was about 20% in the case of 
IL-1α and 28% in the case of IL-1β, or 36 molecules of 
IL-1α or 50 molecules of IL-1β per VLP
315, 316
Table 2 (continued)
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 2
/2
/2
01
7 
12
:1
9:
01
 P
M
 RNA Phage Capsids as Nanotools  Intervirology 2016;59:74–110 
DOI: 10.1159/000449503
91
Table 2 (continued)
Vaccine target Source of epitope Epitope 
length, 
aa1 
Coupling site Comments References
Autoimmune 
arthritis, 
encephalomyelitis 
and myocarditis
IL-17, murine, aa 26 – 158, with a C-terminal 
linker GGGGGC
32 kDa Immunization induced high levels of autoantibodies 
in mice and was effective in ameliorating disease 
symptoms in animal models of autoimmunity. The 
coupling efficiency was about 10%, or 18 IL-17 
homodimers per VLP
317 – 319
Cancer, induction of 
antitumor antibodies
Tumor-associated carbohydrate antigens 
(TACAs): monomeric Tn antigen (GalNAc-
α-O-Ser/Thr) that is overexpressed on the 
surface of a variety of cancer cells including 
breast, colon, and prostate cancer, and is 
involved in aggressive growth and lymphatic 
metastasis of cancers
Carbohy-
drates are 
conjugat-
ed
Lysine residues and 
N-terminus
The antibodies generated in mice were highly selective 
toward Tn antigens and reacted strongly with the 
native Tn antigens on human leukemia cells
235
TACAs: ganglioside GM2, a tetrasaccharide, 
overexpressed in a wide range of tumor cells 
GM2 immobilized on VLPs through a thiourea linker 
elicited high titers of IgG antibodies that recognized 
GM2-positive tumor cells and effectively induced cell 
lysis through complement mediated cytotoxicity
236
Cholesterol lowering Proprotein convertase subtilisin/kexin type 9 
(PCSK9), human, aa 68 – 76, 153 – 163, 
207 – 223
9, 11, 17 Lysine residues Vaccination of mice and macaques led to significant 
reductions in total cholesterol, free cholesterol, 
phospholipids, and triglycerides (table 1) 
296 
Chronic 
inflammatory 
disorders: 
rheumatoid arthritis, 
psoriasis, Crohn’s 
disease
TNF-α, murine, aa 80 – 235 of the TM form, 
aa 4 – 23 peptide: 
CGGSSQNSSDKPVAHVVANHQVE 
156, 20 Immunization by Qβ-TNFα(4 – 23) showed a potential 
to become an effective and safe therapy against 
inflammatory disorders. The coupling efficiency was 
about 60 TNFα 1 – 156 or ~340 TNFα 4 – 23 molecules 
per VLP
320
Chronic 
inflammatory 
illnesses: type 2 
diabetes mellitus
IL-1β, murine, rhesus monkey and human, 
two muteins: mIL-1β (D143K), mIL-1β 
(D143K) with strongly reduced inflammatory 
activity
153 As a potential therapy for the prevention and long-
term treatment of type 2 diabetes, the vaccine showed 
good tolerability in mice and nonhuman primates and 
induced long-lasting, but reversible, IL-1β-neutralizing 
antibody titers, improved glucose tolerance, and 
enhanced insulin secretion in a mouse model of 
diet-induced diabetes. The preclinical study was 
followed by a phase I/II clinical trial in patients with 
type 2 diabetes mellitus using the human version of 
the vaccine hIL1βQβ and the neutralizing IL-1β-
specific antibody response was registered. The epitope 
density was about 0.5 IL-1β molecules per Qβ 
monomer corresponding to a total of 90 IL-1β 
molecules per Qβ VLP
321, 322
Eosinophilia Recombinant IL-5; recombinant eotaxin, 
both murine 
17 and
8 kDa 
Both vaccines overcame self-tolerance and induced 
high antibody titers against the corresponding self-
molecules in mice. Immunization with either of the 
two vaccines reduced eosinophilic inflammation of the 
lung in an ovalbumin based mouse model of allergic 
airway inflammation. The coupling efficiency was 
about 47 or 15% Qβ monomers cross-linked to rIL-5 
or r-eotaxin, respectively, or about 80 – 90 rIL-5 and 
25 – 30 r-eotaxin molecules per VLP
323
Hen egg lysozyme 
(HEL), as a model 
for overcoming 
self-tolerance
Full-length 129 HEL-conjugated VLPs were generated by linking 
biotinylated HEL to biotinylated VLPs using 
streptavidin. The Qβ-HEL VLPs elicited high-titer IgG 
responses against HEL in tolerant sHEL transgenic 
mice in the absence of exogenous adjuvants. 
Therefore, the presentation of HEL onto Qβ VLPs 
allowed overcoming the effects of anergy in the HEL 
mouse model
324
HPV L2 protein, N-terminal HPV16 peptides: aa 
34 – 52, 49 – 71, 65 – 85, 108 – 120, consensus 
65 – 85 peptide
19, 23, 21, 
13
Although all VLP-displayed peptides elicited high-titer 
anti-peptide antibody responses, only a 65 – 85 
peptide-induced response strongly neutralized HPV16 
pseudovirion infection. To overcome HPV type 
specificity, a consensus 65 – 85 peptide was introduced 
and broad neutralizing activity against all of the HPV 
types tested was achieved
208 
Hypertension CYT006-AngQb vaccine: angiotensin II-
derived peptide CGGDRVYIHPF where 
CGG is a linker
11 Successful preclinical trials in mice and rats and phase 
I and IIa clinical trials were performed 
325, 326
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Table 2 (continued)
Vaccine target Source of epitope Epitope 
length, 
aa1 
Coupling site Comments References
Hypertension, 
diabetic 
nephropathy, 
atherosclerosis
ATRQβ-001 vaccine: ATR-001 peptide 
CAFHYESQ corresponding to an epitope of 
the ECL2 of human AT1R, a G-protein 
coupling receptor
8 Lysine residues A successful preclinical trial: the ATRQβ-001 vaccine 
decreased the blood pressure of Ang II-induced 
hypertensive mice and spontaneously hypertensive 
rats. The vaccine provided a promising method to 
treat diabetic nephropathy in rats and atherosclerosis 
in mice
327 – 329
Inflammatory 
hyperalgesia: 
potential long-term 
therapy for chronic 
pain
Nerve growth factor (NGF), murine, aa 
19 – 241 of pro-NGFβ and an additional 9 aa 
extension at the C terminus comprising a 
His6 tag and GGC sequence 
223 Vaccination with NGFQβ substantially reduced 
hyperalgesia in collagen-induced arthritis or 
postinjection of zymosan A, two models of 
inflammatory pain in mice. The coupling efficiency 
was about 60 NGF molecules per VLP
330
Influenza virus M2 protein, N-terminal extracellular domain 23 Intranasal immunization of mice with Qβ VLP-M2 
resulted in strong M2-specific antibody responses as 
well as antiviral protection
226
Hemagglutinin, globular head domain (gH1), 
A/California/07/2009 (H1N1) strain, aa 
49 – 325 and C-terminal extension GGGCG 
281 Preclinical studies of a set of gH1 variants from 
mouse-adapted virus and 2009 H1N1 virus were 
performed. During phase I trial, nonadjuvanted 
gH1-Qβ showed similar antibody mediated 
immunogenicity and a comparable safety profile in 
healthy humans to commercially available vaccines
331 – 333
LCMV Glycoprotein, peptides: p33, KAVYNFATM; 
p13, GLNGPDIYKGVYQFKSVEFD; p33–
gp61, CKSLKAVYNFATMGLNGPDIYKG-
VYQFKSVEF with a GGC linker added to 
the C-terminus
9, 20, 32 The LCMV peptides played crucial role in the studies 
of the CTL induction by the CpG packaging 
222 – 229
Malaria Plasmodium falciparum, CSP, an almost 
full-length CSP consisting of 19 NANP and 3 
NVDP repeats and the majority of the N- 
and C-terminal regions (residues 26Tyr-
127Asp linked to 207Pro–383Ser)
45 kDa By immunization of mice, the Qβ-CSP induced higher 
anti-NANP repeat titers, higher levels of cytophilic 
IgG2b/c antibodies and a trend towards higher 
protection against transgenic parasite challenge as 
compared to soluble CSP formulated in the same 
adjuvant. The coupling efficiency was about 12 – 25%, 
or an average of ~30 CSP molecules per VLP
334
Melanoma Mel-QbG10 vaccine: Melan-A/Mart-1 A27L 
variant peptide CGHGHSYTTAEELAGI-
GILTV Packaging with QbG10 CpG: 
GGGGGGGGGGGACGATCGT-
CGGGGGGGGGG
20 Promising results were obtained by phase I and IIa 
clinical trials on stage II–IV melanoma patients. The 
coupling density reached 160 peptide copies per VLP
335 – 337
Nicotine addiction CYT002-Nic-Qb vaccine, or
NIC002 (formerly known as Nicotine-Qβ or 
Nic-Qβ): nicotine was covalently coupled to 
Qβ VLPs via a succinimate linker
Preclinical studies in mice and successful phase I and 
II clinical trials were performed. Stable vaccine 
formulations enabling storage were developed. An 
experimental comparison to a NIC-CRM vaccine by 
Pfizer was achieved. The coupling density was about 
3.25 nicotine molecules per CP monomer, or 585 
nicotine molecules per VLP
231 – 234, 
338
Obesity Qβ-GIP vaccine: gastric inhibitory peptide 
(GIP, also known as glucose-dependent 
insulinotropic polypeptide), aa 1 – 15 
YAEGTFISDYSIAMD of mature GIP (42 aa) 
with C-terminally added linker GC
15 Immunization of mice with Qβ-GIP vaccine induced 
high titers of specific antibodies and efficiently 
reduced body weight gain in animals fed a high-fat 
diet. Moreover, increased weight loss was observed in 
obese mice vaccinated with VLP-GIP. The coupling 
density was about 1.6 – 2.2 GIP molecules per CP 
monomer
339
Osteoporosis Qβ-TRANCE/RANKL vaccine: TNF-related 
activation-induced cytokine (TRANCE), also 
known as receptor activator of NF-κB ligand 
(RANKL), aa 158 – 316 (extracellular 
domain) of the mature form of murine 
TRANCE/RANKL with a Cys-linker and 
His6 tag
159 Immunization of mice with Qβ-TRANCE/RANKL 
VLPs overcame the natural tolerance of the immune 
system toward self-proteins and produced high levels 
of specific antibodies without the addition of any 
adjuvant. Serum antibodies of immunized mice 
neutralized TRANCE/RANKL activity in vitro and 
were highly active in preventing bone loss in a mouse 
model of osteoporosis. The coupling density was about 
14%, indicating that about one of seven CP monomers 
was covalently attached to a peptide. As TRANCE/
RANKL forms a trimer, ~25 C-TRANCE trimers were 
displayed per VLP
340
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 Chemical Coupling 
 The chemical coupling approach was validated by an 
impressive line of experimental therapeutic vaccines 
 [169, 171] . The idea of therapeutic vaccines is based on 
the assumption that VLP carriers can present surface-
displayed self-antigens and to augment their ability to 
overcome the natural tolerance of the immune system 
toward self-proteins and to induce high levels of specific 
autoantibodies  [216] . Initially, this approach was planned 
as a method to replace host-specific monoclonal anti-
bodies in the treatment of acute and chronic diseases, 
starting with noninfectious diseases  [169] . Therefore, the 
transition from passive administration of monoclonal 
antibodies to active vaccination against self-antigens was 
a logical step in drug development, focusing on afford-
able medicines and broader patient acceptance and regu-
latory compliance. The induction of autoantibodies 
might be beneficial under certain physiological condi-
tions in order to remove unwanted excess of a particular 
self-antigen, such as angiotensin in the case of hyperten-
sion.  Table  2 presents a detailed list of predominantly 
therapeutic vaccines and demonstrates the validity of 
this assumption.
 We included the well-known Qβ VLP-based allergy 
vaccine CYT003-QbG10 that contains an encapsulated 
CpG sequence, so-called QbG10, in  table 2 , although it 
does not carry any attached epitope  [217–221] . However, 
this potentially successful vaccine initially originated 
from epitope-coupling methodology. Moreover, we in-
cluded RNA phage VLPs carrying model epitope p33, 
which is derived from the lymphocytic choriomeningitis 
virus glycoprotein  [222–229] , and epitope D2, which is 
derived from  Salmonella  [230] . Although these are not 
actual vaccine candidates, the model epitopes have played 
a central role in the elucidation of the fine immunological 
mechanisms that govern responses to chimeric VLPs.
 The display of small antigens, such as nicotine  [231–
234] or carbohydrate moieties  [235, 236] , on RNA phage 
VLP surfaces is a novel approach that enabled the gen-
eration of strong immunological responses against non-
peptide antigens and paved the way for the development 
of experimental vaccines against nicotine addiction and 
cancer, respectively. We recommend a recent review on 
novel vaccines constructed on RNA phage VLPs  [237] as 
well as special reviews on vaccines against allergies  [238–
240] , Alzheimer disease  [241] , hypertension  [242–244] , 
influenza  [245, 246] , malaria  [247] , and nicotine addic-
tion  [248–252] .
 Nonvaccine Applications 
 Attention is currently focused on the use of virus-
based nanoparticles as potential scaffolds for novel bio-
materials and as subjects for nanoscale engineering ap-
plications involving exposure to various chemical com-
pounds  [253–256] .
 Drug Delivery by Nanocontainers 
 Table  3 summarizes RNA phage VLP-based experi-
mental approaches that could be classified as VLP pack-
aging and targeting methodologies. Historically, the idea 
of encapsulation/targeting by RNA phage VLPs appeared 
in the early 1990s, only a few years after the vaccine/epi-
tope display approaches described above. A first attempt 
at RNA phage nanocontainer-targeted drug delivery in-
volved, first of all, encapsulation of a deglycosylated ricin 
A chain coupled to an RNA operator stem-loop and dec-
oration of the MS2 VLPs by transferrin  [257–259] . Such 
structures, called ‘synthetic virions’ by the authors, dem-
onstrated high toxicity to leukemia cells carrying trans-
ferrin receptor. A detailed review of these and similar pi-
Vaccine target Source of epitope Epitope 
length, 
aa1 
Coupling site Comments References
Salmonella typhi Outer membrane protein, D2 peptide, aa 
266 – 280 TSNGSNPSTSYGFAN with 
N-terminal CGG linker
18 Lysine residues The vaccine preparations of 13, 56, 94, 142, and 293 
peptides per VLP were used. It was shown that the 
phenomenon of carrier-induced epitopic suppression 
could be overcome by high coupling densities, 
repeated injections and/or higher doses of conjugate 
vaccine (see above for AP205)
230
 The order of data presentation is the same as in table 1. 
1 When a precise number of aa residues is difficult to assess, the size of the epitopes is expressed in kDa.
Table 2 (continued)
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 Table 3.  The RNA phage VLPs as models for nanocontainer packaging and decoration with addressing/targeting/delivery purposes
Interior: packaged by Exterior: decorated by Addressed to Supposed to treat Comments References
AP205 
Random E. coli RNA, 
without any specific 
packaging
HBV, full-length preS1, aa 
13 – 119
Eukaryotic cell lines HepG2, 
Hek293, Jurkat, Namalwa, and 
BHK-21
HBV infection The uptake took place, but seemed cell 
line unspecific and not highly efficient
341
fr
No specific packaging IgG-binding Z domain at the 
C-terminus of the CP 
coexpressed with native CP 
as a helper
Rather unspecific targeting Potentially broad 
applications in 
diagnostics
This is a first example of the 
generation of mosaic VLPs carrying 
the IgG-binding Z domain that could 
be targeted to antibodies displayed on 
the cell surface and used in diagnostics
Jansons and 
Sominskaya, 
unpubl. data
GA
GA operator-specified 
mRNA in vivo
No decoration No cell targeting Broad spectrum of 
potential targets 
Packaging of different mRNAs 
encoding GA coat protein, ENA-78, 
and GFP in vivo in yeast S. cerevisiae
342
HIV-Tat (48 – 60) or WNV E 
protein DIII domain
Human peripheral blood 
mononuclear cells (PBMCs)
PBMC-derived failure Production of mosaic VLPs that are 
packaged by mRNAs encoding IL2 or 
GFP was achieved in vivo in yeast S. 
cerevisiae
343
MS2 operator-specified 
mRNA in vivo
No decoration No cell targeting Broad spectrum of 
potential targets
Introduction of single (S87N, K55N, 
R43K) and double (S87N + K55N and 
S87N + R43K) aa exchanges into the 
GA CP allowed self-assembly and 
packaging of MS2 operator-carrying 
mRNAs in vivo in yeast S. cerevisiae
344
No specific packaging ZHER2:342 affibody, 61 aa in 
length
HER2 receptor on cancer cells Diagnostics/therapy Ability of GA-ZHER2:342 -VLPs to 
recognize selectively and enter the 
HER2 receptor-bearing cells was 
demonstrated. Electron microscopy 
of this construction is presented in 
figure 5
Strods and 
Renhofa, 
unpubl. data
Stromal cell-derived factor 
(SDF1), aa 1 – 41 and 1 – 19
CXCR4 receptor on leukocytes Diagnostics/therapy Insertions at the N-terminus of the 
first or second single-chain dimer 
copy were performed. Some members 
of the family recognized specific cells
MS2 
Ricin A coupled to RNA 
operator; 5-fluorouridine 
coupled to RNA operator
Transferrin, anti-MS2 
antibodies, anti-DF3 
antibodies
Cells of the immune system; 
breast carcinoma and leukemia 
cells 
Broad spectrum of 
potential targets
Classical attempt to use RNA operator 
as a carrier of the desired material 
257, 258 
Antisense 
oligodeoxynucleotides 
(ODNs) targeted to 
human nucleolar protein 
p120 mRNA
Covalent decoration with 
transferrin on the VLP 
surface
Promyelocytic leukemia cell line Acute myelogenous 
leukemia
The ODNs were synthesized as 
covalent extensions to the 19 nt long 
operator sequence 
345 
50 – 70 fluorescein 
molecules conjugated to 
the interior of VLPs 
180 PEG-2000 or PEG-5000 
chains on the exterior of 
VLPs 
Tumor cells Solid tumors An early attempt to construct an 
addressed nanocontainer for the 
potential delivery of therapeutic cargo
262 
Fluorescent dye 
conjugated to the VLP 
interior 
A 41-nt operator-containing 
sequence covalently bound 
to the VLP surface 
Tyrosine kinase receptor on the 
Jurkat T cells
Leukemia Colocalization experiments using 
confocal microscopy indicated that 
the operator-labeled capsids were 
endocytosed and trafficked to 
lysosomes for degradation that could 
allow the targeted drug delivery of 
acid-labile prodrug
265 
Antisense RNA against 
the 5’-UTR and IRES of 
HCV
HIV-1 Tat cell-penetrating 
peptide conjugated 
chemically to VLPs 
Huh-7 cells containing an HCV 
reporter system
Chronic HCV The packaged antisense RNA showed 
an inhibitory effect on the translation 
of HCV genome
346
Fluorescent dyes as donor 
chromophores 
Zinc porphyrins capable of 
electron transfer
No cell targeting No definite target 
disease specified 
Specific positioning allowed energy 
transfer and sensitization of the 
porphyrin at previously unusable 
wavelengths, as demonstrated by the 
system’s ability to effect a 
photocatalytic reduction reaction at 
multiple excitation wavelengths
266 
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Interior: packaged by Exterior: decorated by Addressed to Supposed to treat Comments References
Coupling of 180 
porphyrins capable of 
generating cytotoxic 
singlet oxygen upon 
illumination
∼20 copies of a Jurkat-
specific aptamer 
Jurkat leukemia T cells Leukemia The doubly modified VLPs were able 
to target and kill Jurkat cells selectively 
even when mixed with erythrocytes
267 
Nanoparticles, 
chemotherapeutic drugs, 
siRNA cocktails, and 
protein toxins
SP94 peptide that binds 
human hepatocellular 
carcinoma (HCC) cells 
Hep3B cells HCC The targeted VLPs loaded with 
doxorubicin, cisplatin, and 
5-fluorouracil selectively killed the 
HCC cell line, Hep3B. Encapsidation 
of a siRNA cocktail induced growth 
arrest and apoptosis of Hep3B cells. 
Loading of VLPs with ricin toxin 
A-chain killed the entire population of 
Hep3B cells
268
Micro-RNA: pre-miR 
146a
Particles conjugated with 
HIV-1 Tat(47 – 57) peptide
Human PBMCs Systemic lupus 
erythematosus, 
osteoclastogenesis
Restoring the loss of miR-146a was 
effective in eliminating the production 
of autoantibodies
347 – 349
RNA conjugate 
encompassing a siRNA 
and the operator sequence
Covalent attachment of 
human transferrin
HeLa cells Potentially broad 
applications
The VLPs entered cells via receptor-
mediated endocytosis and produced 
siRNA effects better than by 
traditional lipid transfection route
350
Gold nanoparticles Alexa Fluor 488 (AF 488) 
labelled DNA strands
No cell targeting No definite target 
disease specified 
The VLP architecture by placing the 
dye at distances of 3, 12, and 24 bp 
from the surface of VLPs bearing 
10-nm gold nanoparticles allowed the 
rapid exploration of many variables 
involved in metal-controlled 
fluorescence
351
Porphyrin: loaded with 
approximately 250 
cationic porphyrins 
through a novel assembly 
packaging mechanism
Cancer cells targeting 
nucleic acid aptamers via 
chemical conjugation
MCF-7 human breast cancer 
cells
Breast cancer upon 
photoactivation
The MCF-7 cells incubated with 
targeted, porphyrin-loaded virus 
capsids exhibited cell death. The 
strategy offered an approach for 
efficient targeted delivery of 
photoactive compounds for site-
specific photodynamic cancer therapy
352
Various reporters to be 
used by fluorescence-
based flow cytometry, 
confocal microscopy, and 
mass cytometry
Antibodies using a rapid 
oxidative coupling strategy
Antibody-capsid conjugates are 
targeting extracellular receptors 
on human breast cancer cell 
lines
Breast cancer The broad set of conjugates with 
various reporters on the interior of 
VLPs may lead to many clinically 
relevant applications, including drug 
delivery and in vivo diagnostics
353
Long noncoding RNA: 
MEG3 RNA 
GE11, a dodecapeptide 
YHWYGYTPQNVI, ligand 
of epidermal growth factor 
receptor (EGRF), chemically 
coupled
EGFR HCC cell line The targeted delivery was dependent 
on clathrin-mediated endocytosis and 
MEG3 RNA suppressed tumor growth 
mainly via increasing the expression 
of p53 and its downstream gene 
GDF15, but decreasing the expression 
of MDM2
354
LacZ RNA fused to RNA 
operator
No decoration No cell targeting Potentially broad 
applications
This is a classical attempt to ensure 
operator-specific packaging in vivo 
156 
MS2 operator sequence 
linked to the human 
growth hormone mRNA 
for in vivo packaging in S. 
cerevisiae 
No definite target 
disease specified
This is a sort of application belonging 
to the ‘armored RNA’ technology. 
Functionality of packaged mRNA was 
confirmed by translation of mRNAs 
purified from VLPs
74 
Taxol Breast, lung, and 
ovarian cancers
Aa exchange N87C on the interior of 
VLP allowed use of sulfhydryl groups 
for the attachment of taxol, a potent 
chemotherapeutic, as a cargo
264 
HIV-1 gag mRNAs (1544 
bases) produced in S. 
cerevisiae
HIV/AIDS: as a vaccine The HIV antigen-specific antibody 
responses were elicited by 
immunization of BALB/C mice
355
Alkaline phosphatase 
tagged with a 16 aa 
peptide
No definite target 
disease specified 
This is a first attempt to encapsulate 
enzymes where the encapsulated 
enzyme had the same K(m) value and 
a slightly lower k(cat) value than the 
free enzyme
356
Table 3 (continued)
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Interior: packaged by Exterior: decorated by Addressed to Supposed to treat Comments References
mRNA joined to 19-nt 
operator/aptamer
Macrophages Prostate cancer The packaged mRNA ensured strong 
humoral and cellular immune 
responses and protected mice as a 
therapeutic vaccine against prostate 
cancer
357
No specific packaging Tumor cell-specific peptides Tumor cells Solid tumors Three peptides known to target 
specific tissues: (i) neuroblastoma and 
breast cancer cell lines, (ii) matrix 
metalloproteinases, (iii) kidney were 
chosen as attachment models
263 
Conjugation of azide- and 
alkyne-containing proteins 
(an antibody fragment and 
the granulocyte-macrophage 
colony stimulating factor), 
nucleic acids, and PEG
Broad spectrum of potential 
targeting
Tumors and other 
possible targets
This is a universal approach based on 
the inclusion of surface exposed 
methionine analogues 
(azidohomoalanine and 
homopropargylglycine) containing 
azide and alkyne side chains by cell-
free synthesis technology
174 
Qβ
CpG ODNs With and without specific 
addressing 
Cells of immune system Potentially broad 
applications
This is a classic example of the ODN 
encapsulation for the broad clinical 
applications as prophylactic and/or 
therapeutic vaccines
217 – 229
∼60 Alexa Fluor 568 
fluorophores per VLP
Fullerene C60 and PEG HeLa cell line Cancer This approach overcame the 
insolubility of C60 in water and opened 
the door for the applications in 
photoactivated tumor therapy
358
Metalloporphyrin 
derivative for 
photodynamic therapy
Glycan ligand for specific 
targeting of cells bearing the 
CD22 receptor
CD22 receptor This approach benefited from the 
presence of the strong targeting 
function and the delivery of a high 
local concentration of singlet oxygen-
generating payload
359, 360 
Aptamers embedded in a 
longer RNA sequence 
with the Qβ CP operator
No decoration No cell targeting Potentially broad 
applications in therapy
The VLPs ensured the delivery of the 
encapsulated aptamers that were 
protected from degradation and 
retained ability to bind their small-
molecule ligands
361, 362
Positively charged 
synthetic polymer by 
atom transfer radical 
polymerization (ATRP) 
methodology 
Potentially broad 
applications in therapy 
and imaging 
diagnostics
This is a robust method for removing 
encapsidated RNA from VLPs and the 
use of the empty interior space for 
site-specific, ‘graft-from’ ATRP 
reactions
363
Proteins: 25-kDa 
N-terminal aspartate 
dipeptidase, peptidase E, 
62-kDa firefly luciferase 
(Luc), a thermostable 
mutant of Luc
No definite target 
disease specified
The encapsulated enzymes were 
stabilized against thermal degradation, 
protease attack, and hydrophobic 
adsorption
364
No specific packaging Copper (I)-catalyzed azide-
alkyne cycloaddition 
reaction
Variety of cells Potentially broad 
applications
Bioconjugations of Qβ VLPs 
derivatized with azide moieties at 
surface lysine residues were 
performed. Complete derivatization of 
more than 600 reactive sites per 
particle was achieved
365
Glycans used as substrates 
for glycosyltransferase 
reactions to build di- and 
trisaccharides
Cognate receptors on the 
appropriate beads and cells
Potentially broad 
applications
The elaborated methodology provided 
a convenient and powerful way to 
prepare complex carbohydrate ligands 
for clustered receptors
366, 367
Cationic aa motifs by genetic 
engineering or chemical 
conjugation
Inhibiting the anticoagulant 
action of heparin 
Clinical overdose of 
heparin
The polycationic motifs displayed on 
the mutated Qβ VLPs acted as heparin 
antagonists
368 – 370
IgG-binding Z domain at the 
C-terminus of the CP 
coexpressed with native CP 
as a helper
Rather unspecific targeting Potentially broad 
applications in 
diagnostics
This presents generation of mosaic 
VLPs carrying the IgG-binding Z 
domain that could be targeted to 
antibodies displayed on the cell 
surface or used in diagnostics
371
Table 3 (continued)
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oneering experiments was published in 2002  [260] . An-
other detailed review devoted to anticancer perspectives 
of nanoparticles filled with siRNA was recently published 
 [261] .
 The next step in the development of VLP packaging/
targeting technology included the chemical coupling of 
putative cargo and targeting molecules to the outer and 
inner surfaces of VLPs, respectively  [175, 262–267] . It has 
been demonstrated that MS2 VLPs can be conjugated to 
peptides recognizing human hepatocellular carcinoma 
cells and can be loaded with vastly different types of car-
go, including low molecular weight chemotherapeutic 
drugs, siRNA cocktails, protein toxins and nanoparticles, 
resulting in the selective killing of target cells  [268] . The 
packaging of Qβ VLPs with immunostimulatory CpG se-
quences led not only to the development of potential al-
Interior: packaged by Exterior: decorated by Addressed to Supposed to treat Comments References
No specific packaging Oligomannosides that are 
modelling the ‘glycan shield’ 
of HIV envelope
No cell targeting HIV/AIDS as a model The oligomannose clusters were 
recognized by monoclonal anti-HIV 
antibody, but did not induce 
antibodies against the HIV epitopes by 
immunization of rabbits
372
Transferrin Transferrin receptors Potentially broad 
applications in 
diagnostics and therapy
This approach allowed cellular 
internalization of chimeric VLPs 
through clathrin-mediated 
endocytosis
373
DNA No cell targeting Potentially broad 
applications in 
nanotechnology
A noncompact lattice was created by 
DNA-programmed crystallization 
using surface-modified Qβ VLPs and 
gold nanoparticles, engineered to have 
similar effective radii
374
Poly(2-oxazoline) No cell targeting Potentially broad 
applications in 
diagnostics and therapy
This showed that the size and content 
of VLP-polymer constructs could be 
controlled by changing the polymer 
chain length and attachment density. 
The system is universal because of the 
convenient click chemistry 
applications
375
Conjugation of azide- and 
alkyne-containing proteins
Broad spectrum of potential 
targeting
Tumors and other 
possible targets
See above, the same for MS2 174 
Modification via the copper-
catalyzed azide-alkyne 
cycloaddition (CuAAC) 
reaction
No definite cell targeting 
specified 
Potentially broad 
applications in therapy 
and imaging 
diagnostics
This is a methodology to use VLPs as 
multivalent macroinitiators for ATRP 
376
Human EGF as a C-terminal 
fusion to the Qβ CP
EGF receptor Therapy based on 
interactions with cells 
overexpressing their 
cognate receptor
Mosaic particles with an 
approximately 5 – 12 EGF molecules 
on the VLP surface were obtained. 
The particles were found to be 
amenable to bioconjugation by 
standard methods as well as the 
high-fidelity CuAAC reaction
377
Sulfate groups that elicit 
heparin-like anticoagulant 
activity
No cell targeting Blood coagulation – as 
heparin-like drugs
Following conversion of VLP surface 
lysine groups to alkynes, the sulfated 
ligands were attached to the VLP via 
CuAAC; 3 – 6 attachment points per 
CP monomer were modified via 
CuAAC. The sulfated VLPs were able 
to perturb coagulation
378, 379
Polynorbornene block 
copolymers
No cell targeting Potentially broad 
applications in therapy 
and imaging 
diagnostics
Poly(norbornene-PEG)-b-
poly(norbornene anhydride) of three 
molecular masses: 5, 10, and 15 kDa 
were added to lysine residues
380
φCb5
Gold nanoparticles, 
tRNA, diphtheria toxin, 
mRNA, CpG
No decoration No cell targeting Potentially broad 
applications in therapy
The ease with which the φCb5 CP 
dimers can be purified and 
reassembled into VLPs makes them 
attractive for the internal packaging of 
nanomaterials and the chemical 
coupling of peptides
77
 The data are presented in alphabetical order of the phage model. For each model, the studies are ordered chronologically, but at first presenting studies describing both packaging 
and decoration, then data with packaging only, and then data with decoration only.
Table 3 (continued)
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lergy vaccines (see above) but also strongly contributed to 
the general understanding of the mechanics of oligode-
oxynucleotide-induced stimulation  [217–229, 269, 270] .
 Imaging 
 The use of imaging agents in combination with RNA 
phage VLPs has contributed to the high-resolution and 
noninvasive visualization of these particles, as well as to 
the potential treatment of diseases  [254] . The RNA phage 
VLP-based applications that have been developed as im-
aging technologies are compiled in  table 4 . The first stud-
ies on the generation of nanoparticles for magnetic reso-
nance imaging applications and the first comparisons of 
interior versus exterior cargo strategies appeared in the 
 Table 4.  The bioimaging agents on the basis of RNA phage VLPs and virions
Contrast agent Comments References
MS2
MS2 phage was labeled with the succinimidyl ester of [Ru(2,2′-
bipyridine)2(4,4′-dicarboxy-2,2′-bipyridine)]2+ (RuBDc), which is a very 
photostable probe that possesses favorable photophysical properties, including 
a long lifetime, high quantum yield, large Stokes’ shift, and highly polarized 
emission. The RuBDc luminophore attacks lysine residues
The intensity and anisotropy decays of RuBDc when conjugated to RNA phage 
MS2 were examined using frequency domain fluorometry with a high-intensity, 
blue light-emitting diode (LED) as the modulated light source. The results showed 
that RuBDc can be useful for studying rotational diffusion of biological 
macromolecules
381
The MS2(Gd-DTPA-ITC)m contrast agent was synthesized through the 
conjugation of premetalated Gd-DTPA-ITC (2-(4-isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid) to the lysine residues of MS2 VLPs (not 
phage) on the VLP exterior
An MRI contrast agent was developed by conjugation of more than 500 Gd chelate 
groups onto a VLP. The high density of paramagnetic centers and slow tumbling 
rate of modified VLPs provided enhanced T1 relaxivities up to 7,200 mM–1s–1 per 
particle. A bimodal imaging agent was generated by sequential conjugation of 
fluorescein and Gd3+ chelate
271
In order to maximize the relaxivity of each Gd3+ complex attached to the phage 
scaffold, hydroxypyridonate-based contrast agents were used. The interior 
(Tyr85) and exterior (Lys106, Lys113, and the N-terminus) surfaces of ‘empty’ 
phage were targeted independently through the appropriate choice of reagents
The phage capsids sequestering the Gd-chelates on the interior surface (attached 
through tyrosine residues) not only provided higher relaxivities than their exterior 
functionalized counterparts (which relied on lysine modification) but also 
exhibited improved water solubility and capsid stability. There are strong 
advantages to using the internal surface for contrast agent attachment, leaving the 
exterior surface available for the installation of tissue targeting groups
272, 382
The ‘empty’ shell of phage was labeled on its inside surface with [18F]
fluorobenzaldehyde through a multistep bioconjugation strategy. An aldehyde 
functional group was first attached to interior tyrosine residues through a 
diazonium coupling reaction. The aldehyde was further elaborated to an 
alkoxyamine functional group, which was then condensed with [18F]
fluorobenzaldehyde
This is a first example of the positron emission tomography (PET) radiolabels that 
have been developed on RNA phages. Relative to fluorobenzaldehyde, the 
fluorine-18-labeled MS2 exhibited prolonged blood circulation time and a 
significantly altered excretion profile
273 
Approximately 125 xenon MRI sensor molecules were incorporated in the 
interior of an MS2 VLPs, conferring multivalency and other properties of the 
VLP to the sensor molecule 
The resulting signal amplification facilitated the detection of sensor at 0.7 pM, the 
lowest to that date for any molecular imaging agent used in magnetic resonance. 
This amplification promised the detection of chemical targets at much lower 
concentrations than would be possible without the VLP scaffold
383
The PET imaging characteristics were improved by the usage of PEG chains 
added to MS2 VLPs. The MS2- and MS2-PEG VLPs possessing interior DOTA 
chelators and labeled with 64Cu were compared by injecting intravenously into 
mice possessing tumor xenografts
The biodistribution and circulation properties of the VLP-based PET imaging 
agents were investigated carefully in order to realize the potential of such agents 
for the future use in in vivo applications
384 
The VLPs were modified using an oxidative coupling reaction, conjugating 
∼90 copies of a fibrin-targeting peptide to the exterior of each protein shell. 
The installation of near-infrared fluorophores on the interior surface of the 
capsids enabled optical detection of binding to fibrin clots. The targeted 
capsids bound to fibrin, exhibiting higher signal-to-background ratios than 
control, nontargeted VLP-based nanoagents
The chemically functionalized and specifically targeted VLPs were used for fibrin 
imaging. The modified capsids outperformed the free peptides and were shown to 
inhibit clot formation at effective concentrations over 10-fold lower than the 
monomeric peptide alone. The in vitro assessment of the capsids suggests that 
fibrin-targeted VLPs could be used as delivery agents to thrombi for diagnostic or 
therapeutic applications
385
PP7
Technetium-99m labeling of PP7 phage was achieved by a HYNIC bifunctional 
agent. Radiochemical purity higher than 90% was obtained
The labeled PP7 phage was used as a specific tracer of P. aeruginosa infection in 
animals
386
Qβ
The VLPs were decorated with gadolinium complexes using the CuI-mediated 
azide-alkyne cycloaddition reaction. The interior surface labeling was 
engineered by the introduction of an azide-containing unnatural amino acid 
into the CP
The circulation lifetime, plasma clearance, and distribution in major organs were 
studied in mice for contrast agents based on original VLPs and VLPs with mutated 
surface aa residues
387
R17
The metal-ligand complex, [Ru(2,2′-bipyridine)(2)(4,4′-dicarboxy-2,2′-
bipyridine)]2+ (RuBDc), was used as a spectroscopic probe for studying the 
hydrodynamics of biological macromolecules
The combination of the use of a long-lifetime Ru(II) metal-ligand complexes with 
blue LED excitation allowed the performance of time-resolved intensity and 
anisotropy decay measurements with a simpler and lower-cost instrument
388
 The order of data presentation is the same as in table 1.
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mid 2000s  [271, 272] . Following these reports, MS2 VLPs 
were loaded with positron emission tomography radiola-
bels  [273] . To date, MS2 phages and VLPs have played a 
leading role in bioimaging studies.
 Armored Polynucleotides for Diagnostic Applications 
 The ‘armored’ nucleic acids are useful as noninfec-
tious, easily available reagents for the quality control in 
the diagnosis of pathogenic viruses like HCV (hepatitis C 
virus). As an example of ‘armored RNA’ technology, MS2 
VLPs were made to perform in vivo encapsidation of a 
desired RNA, which was accomplished by including the 
MS2 operator sequence on the RNA molecule to enable 
its packaging. The armored RNA was therefore protected 
from RNase digestion  [274] . Recently, the creation of ar-
mored dsDNA using HBV and HPV particles was accom-
plished on the basis of previous work using MS2 VLPs 
 [275] . Armored RNAs have multiple uses, such as for the 
detection of HCV, severe acute respiratory syndrome 
coronavirus, and influenza virus RNA  [276] or for the 
creation of unique RNA molecules harboring both tRNA 
and mRNA functions  [277] . Perspectives on the produc-
tion and practical use of MS2 VLPs for routine diagnos-
tics including food quality control were discussed in a re-
cent review  [278] .
 Future Perspectives 
 The next milestones for the development of the RNA 
phage VLP field are presented in  figure 6 . The major ten-
dency provides the combination of both (i) decoration of 
the VLP scaffolds with molecules of interest and (ii) pack-
aging of foreign material into VLP nanocontainers.
 Vaccine Design 
 Vaccines  will remain a classic area for the application 
of RNA phage VLPs  [279] . For example, clear progress in 
vaccine formulation and storage was achieved through a 
MS2 VLP-based papillomavirus vaccine  [280] . RNA 
phage CP properties can be used in combination with 
other possible vaccine carriers, such as retroviral plat-
forms, with a special goal to improve RNA packaging and 
delivery  [281] .
 Peptide Display 
 MS2 VLPs  [160] and Qβ phage  [32] offer favorable al-
ternatives to filamentous bacteriophages for the display 
of immunologically active peptides. Recently, a tumor-
associated antigen was identified using MS2 peptide-dis-
play technology  [282] , confirming the importance of such 
a methodology for future studies.
 Nanomachines 
 RNA phage VLPs are regarded as potential compo-
nents of future nanomachines, which is a general term for 
a machine ranging in size from 1 nm to 1 μm. Perspectives 
on the revolutionary nanoscale engineering of RNA 
phage VLPs as natural prefabricated scaffolds to contain 
molecules in precisely defined arrays were described in a 
recent review  [253] . The future of VLP-derived materials 
[for chemical strategies and details of VLP bioconjuga-
tion technologies, see  283 ] is quite impressive because the 
number of methods that can be used to change both the 
interior and exterior surfaces of capsids by the incorpora-
tion of organic and inorganic compounds is unlimited. 
Further development of VLPs with defined antigenic and 
immunogenic properties, as well as VLPs with improved 
 Fig. 6. General milestones of the development of RNA phage VLPs 
as nanotools. The 3D structure of the MS2 phage is presented at 
the top.  
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packaging and targeting capabilities, will create novel vi-
ral nanotechnology applications and is expected to pro-
duce nanomachines with rationally designed characteris-
tics. For example, an interesting new approach is exem-
plified by the use of DNA as a scaffold to arrange MS2 
VLPs into one-dimensional arrays with precise nanoscale 
positioning  [284] . Such bioinspired plasmonic nano-
structures may provide a flexible design base for manipu-
lating photonic excitation and photoemission  [285] .
 Search for New RNA Phage Vectors 
 The clear differences that exist in RNA phage VLP 
structures, stabilities, and reconstruction capacities have 
provoked extensive studies aimed at identifying novel 
members of the Leviviridae family. Out of such efforts, 19 
new genomes of icosahedral RNA phages  [286] , genomes 
from the phages M  [287] , C-1 and HgalI  [288] , DL52 and 
DL54  [289] , from a so-called JS-like group  [290] and of 
the phages EC and MB  [291] , have been described.
 A recent survey of metagenomic databases revealed 
158 partial single-stranded RNA phage genome sequenc-
es belonging to about 120 distinct phylotypes  [292] . Sixty-
six of the genomes contained a putative open reading 
frame predicted to be the CP  [292] . Novel RNA phage 
sequences were present in samples collected from a range 
of ecological niches worldwide, including invertebrates 
and extreme microbial sediment, demonstrating that 
they are more widely distributed than previously recog-
nized  [292] . These genomes are expected to undergo 
studies of CP gene expression as well as elucidation of 
their 3D capsid structures, and will potentially serve in 
new applications.
 Structural Studies 
 3D structural investigations have revealed unexpected 
capabilities of RNA phage capsids, such as their ability
to transform into T = 1  [77] or rod-like  [157] structures. 
Moreover, such studies have contributed worthwhile in-
formation towards understanding protein folding and vi-
rus assembly  [293] . Additional important directions for 
future studies involve the elucidation of VLP surface 
properties in the context of the presence of internal RNA, 
as reported previously  [294] , and/or the external display 
of foreign sequences of different origins, such as oligo-
nucleotides, peptides, sugars, and metal ions. Such stud-
ies would be helpful for the prediction of VLP character-
istics in the context of aqueous and nonaqueous media, 
as well as under different biological conditions, which 
should facilitate the use of these particles as vaccines and/
or gene therapy tools.
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